Canine Coronavirus

Overview and Taxonomy of Canine Coronavirus (CCoV)

Canine coronavirus (CCoV) is a highly contagious, enveloped, single-stranded positive-sense RNA virus belonging to the family Coronaviridae, subfamily Orthocoronavirinae, genus Alphacoronavirus, and species Alphacoronavirus 1 [5, 6, 15]. This species complex also encompasses feline coronavirus (FCoV) and transmissible gastroenteritis virus (TGEV) of swine, underscoring the close evolutionary relationships and potential for inter-species transmission among these pathogens [6, 21]. The CCoV virion is pleomorphic, typically spherical, with a diameter of 80–120 nm, and is characterized by the classic club-shaped S (spike) glycoprotein projections emanating from the lipid envelope, giving it the hallmark “corona” or crown-like appearance under electron microscopy [17]. The viral genome, approximately 27–32 kb in length, is organized with a canonical coronavirus architecture: a 5′ untranslated region (UTR), a large replicase gene (ORF1a/b) encoding non-structural proteins (nsps) that form the replication-transcription complex, followed by structural protein genes in the order S (spike), E (envelope), M (membrane), and N (nucleocapsid), interspersed with various accessory genes (e.g., ORF3abc, ORF7b) that are often strain- and genotype-specific and contribute to viral pathogenesis and host range [7, 21].

Genotypic Classification and Subtypes

The taxonomic landscape of CCoV has evolved considerably over the past two decades, driven by extensive genomic characterization and the recognition of distinct genetic lineages. Initially, CCoV was classified into two main genotypes, CCoV type I (CCoV-I) and CCoV type II (CCoV-II), based on antigenic differences and phylogenetic analyses of the S gene [6, 21]. These two genotypes share up to 96% nucleotide identity across the genome but exhibit profound divergence in the S gene, which encodes the primary determinant of host cell receptor binding and viral entry [6]. This divergence has significant implications for tissue tropism, pathogenicity, and immune evasion.

The classification was further refined following the seminal discovery of a novel CCoV type II variant in 2009, which likely originated from a double recombination event between classical CCoV-II and TGEV [6, 15]. This led to the proposed subdivision of CCoV-II into two subtypes: CCoV-IIa, encompassing the classical CCoV-II strains, and CCoV-IIb, which includes TGEV-like recombinant CCoVs that possess a spike gene more closely related to TGEV [6, 15, 21]. This subtype distinction is not merely taxonomic; it reflects fundamental differences in the S1 domain, particularly the N-terminal domain (NTD), which in CCoV-IIb mediates sialic acid binding, a feature shared with TGEV and associated with enteric tropism [13]. The emergence of CCoV-IIb highlights the remarkable plasticity of coronaviruses and their capacity for genetic exchange through recombination, a process that is a major driver of their evolution and emergence.

Genomic Architecture and Recombination

The CCoV genome is a hotbed of recombination, a phenomenon that has been extensively documented and is central to the generation of genetic diversity. Recombination events can involve large genomic fragments spanning multiple genes, as exemplified by the CCoV-IIb lineage [6], or more localized events within specific genes, such as the S gene. For instance, recombination analyses have identified numerous recombinant strains circulating globally, including strains in China that are chimeras of CCoV-I and CCoV-II [4, 10], and a notable recombinant between FCoV and CCoV (HLJ-071) that displayed an FCoV-like S gene and was capable of replicating in canine macrophages [16]. Another striking example is the identification of CCoV-HuPn-2018, a novel canine-feline recombinant alphacoronavirus isolated from a human pneumonia patient in Malaysia, whose genome is a mosaic of CCoV and FCoV sequences, with its S gene showing high identity to FCoV-II in the S2 domain [9, 13]. These recombination events are not random; they are often facilitated by co-infection of a single host with multiple coronaviruses, which is a common occurrence in dogs, particularly those in high-density settings like shelters [2, 8]. The high prevalence of co-infections with CCoV-I and CCoV-IIa, as well as with other enteric viruses, provides ample opportunity for template switching during RNA replication, driving the continuous evolution of novel variants [2, 8, 10].

Host Range and Cross-Species Transmission

While CCoV is primarily considered a pathogen of domestic dogs (Canis lupus familiaris), its host range is far broader and expanding. Molecular evidence has confirmed natural CCoV infections in a diverse array of wild carnivores, including red foxes (Vulpes vulpes) [1], golden jackals (Canis aureus) [1], raccoon dogs (Nyctereutes procyonoides) [11], bush dogs (Speothos venaticus) [18], Italian wolves (Canis lupus italicus) [19], and even captive snow leopards (Panthera uncia) [3] and an Amur tiger (Panthera tigris altaica) [20]. A particularly severe outbreak of acute diarrhea in farmed foxes (Vulpes spp.) in China, caused by a novel CCoV lineage designated VuCCoV, resulted in over 39,600 deaths between 2019 and 2022, demonstrating the potential for CCoV to cause devastating epizootics in non-canine hosts [7]. These cross-species transmission events are facilitated by the use of the aminopeptidase N (APN) receptor, which is highly conserved among carnivores. The APN proteins of wild felids, for instance, share >95.7% amino acid identity with that of the domestic cat, explaining the susceptibility of snow leopards to CCoV-II [3]. Similarly, the spike protein of VuCCoV was shown to bind efficiently to both canine and fox APN, enabling its spillover and adaptation to foxes [7]. These findings underscore the crucial role of domestic and wild carnivores as mixing vessels for alphacoronaviruses, where co-infection can generate novel recombinants with altered host range and pathogenic potential [3].

Zoonotic Potential and Global Public Health Implications

The emergence of CCoV-HuPn-2018, isolated from nasopharyngeal swabs of children hospitalized with pneumonia in Malaysia, has fundamentally challenged the previous paradigm that CCoV is a strictly animal pathogen [6, 9, 15]. This virus, classified as a novel canine-feline recombinant alphacoronavirus, represented the first documented evidence of a CCoV spillover into humans [9]. Subsequent identification of a nearly identical virus (HuCCoV_Z19Haiti) in a traveler returning from Haiti to the United States provided further evidence that such zoonotic infections are not isolated events [6, 12]. These discoveries have prompted the World Health Organization (WHO) and the World Organisation for Animal Health (WOAH) to recognize the potential public health threat posed by animal coronaviruses, emphasizing the need for a One Health approach to surveillance [6]. The CCoV-HuPn-2018 spike gene exhibits a unique N-terminal subdomain (0-domain) with sequence similarity to TGEV and CCoV-IIb, but with evidence of relaxed selection pressure and a loss of sialic acid binding function, a change that is hypothesized to have facilitated a shift from enteric to respiratory tropism, analogous to the evolution of porcine respiratory coronavirus (PRCV) from TGEV [13]. This adaptive loss of function in the 0-domain may have been a key step in enabling the virus to infect the human respiratory tract. The high mutation rate and recombination frequency of CCoV, combined with its expanding host range and demonstrated ability to cross species barriers, position it as a virus of significant zoonotic concern, warranting continuous molecular surveillance at the animal-human interface [6, 14].

Molecular Pathogenesis of Canine Coronavirus Infection

Canine coronavirus (CCoV), an enveloped, single-stranded positive-sense RNA virus belonging to the species Alphacoronavirus-1 within the family Coronaviridae, represents a paradigm of molecular adaptation and pathogenic plasticity. While historically regarded as an agent of mild, self-limiting enteritis, contemporary research has unveiled a sophisticated interplay between viral determinants and host cellular machinery that governs tissue tropism, immune evasion, systemic dissemination, and, critically, the capacity for cross-species transmission [6, 15]. The molecular pathogenesis of CCoV infection is a multi-faceted process orchestrated by the virus’s genomic architecture, its exploitation of host signaling pathways, and its remarkable propensity for genetic recombination and mutation. Understanding these molecular underpinnings is not merely an academic exercise; it is essential for predicting the emergence of virulent variants, developing targeted antiviral interventions, and assessing zoonotic risk, a concern highlighted by the World Organisation for Animal Health (WOAH) and the Centers for Disease Control and Prevention (CDC) regarding the potential for animal coronaviruses to adapt to human hosts.

Viral Entry and Receptor Engagement: The Aminopeptidase N Axis

The molecular cascade of CCoV infection is initiated by the interaction of the viral spike (S) glycoprotein with the host cell receptor, aminopeptidase N (APN), also known as CD13. CCoV type II (CCoV-II) utilizes APN for cellular entry, a mechanism shared with feline coronavirus type II (FCoV-II) and transmissible gastroenteritis virus (TGEV) [3, 11]. The S protein, a class I fusion protein, comprises two functional subunits: the N-terminal S1 domain, which harbors the receptor-binding domain (RBD), and the C-terminal S2 domain, which mediates membrane fusion. Molecular docking and binding studies have demonstrated that the RBD of CCoV-IIa subtypes exhibits robust binding to canine APN, but critically, shows no significant affinity for human APN, defining a key species barrier [11]. However, the plasticity of this interaction is a central theme in CCoV pathogenesis. The emergence of a novel canine-feline recombinant alphacoronavirus, CCoV-HuPn-2018, isolated from pneumonia patients in Malaysia, underscores the potential for receptor usage adaptation [9, 12, 13]. Comparative evolutionary analyses of the CCoV-HuPn-2018 S gene reveal a complex recombinant history involving FCoV-II and TGEV-like sequences, particularly within the N-terminal domain (NTD or 0-domain) of the S1 subunit [13]. This 0-domain, responsible for sialic acid binding and enteric tropism in TGEV, shows evidence of relaxed selection pressure and unique amino acid substitutions in CCoV-HuPn-2018. It is hypothesized that mutations in this sialic acid-binding region may lead to a loss of enteric tropism and a shift towards respiratory tract infection, analogous to the evolution of porcine respiratory coronavirus (PRCV) from TGEV [13]. This tropism shift is a critical molecular event, enabling a virus typically confined to the gastrointestinal epithelium to access the respiratory tract of a new host species.

Intracellular Hijacking: Modulation of Host Signaling and Stress Pathways

Once internalized, CCoV actively subverts host cellular processes to create a permissive environment for replication. A pivotal host factor co-opted by CCoV is the aryl hydrocarbon receptor (AhR), a ligand-activated transcription factor with pleiotropic roles in xenobiotic metabolism, inflammation, and immune regulation. In vitro infection of A72 canine fibrosarcoma cells with CCoV-II leads to substantial activation of AhR signaling, as evidenced by increased protein levels [34]. This activation is not a passive consequence of infection; rather, it appears to be a requisite for efficient viral replication. Pharmacological inhibition of AhR using CH223191 results in a meaningful decline in virus yield and a reduction in viral nucleocapsid (N) protein expression, accompanied by a suppression of cell death and improved viability [34]. The mechanism by which AhR promotes CCoV replication is an area of active investigation, but its link to the modulation of interferon responses and cellular metabolism is a likely contributor. The pathological relevance of this pathway is further emphasized by studies on the environmental contaminant 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a potent AhR agonist. TCDD exposure during CCoV infection substantially enhances virus yield and N protein expression, exacerbates cytopathic effects, and modulates AhR signaling [22]. This finding establishes a direct molecular link between environmental toxicology and viral pathogenesis, suggesting that exposure to certain pollutants can intensify CCoV disease by hijacking the same receptor the virus itself exploits. Conversely, fungal secondary metabolites that inhibit AhR, such as 3-O-methylfunicone (OMF), vermistatin, and 6-pentyl-α-pyrone, demonstrate potent antiviral activity, further solidifying AhR as a critical host dependency factor [27, 31, 35].

Parallel to AhR, the formyl peptide receptor 2 (FPR2) has emerged as another key modulator of CCoV pathogenesis. FPR2 is a G protein-coupled receptor involved in the innate immune response, particularly in the recruitment and activation of phagocytes. During CCoV infection of A72 and CRFK cells, specific inhibition of FPR2 using the antagonist WRW4 leads to a dramatic enhancement of viral replication, a significant increase in N protein expression, and worsened cytopathic effects [26]. In a striking mirror image, treatment with the FPR2 agonist HP2-20 suppresses viral replication and ameliorates cell viability [26]. These results suggest that FPR2 signaling acts as a natural antiviral brake during CCoV infection, and that the virus may benefit from its suppression. The differential binding modes of the antagonist and agonist to the canine FPR2 model, with WRW4 confined to the receptor core and HP2-20 interacting with both the core and the second extracellular loop (ECL2), provide a structural basis for these divergent functional outcomes [26]. The study implicates FPR2 as an interesting target for therapeutic intervention, where receptor activation could harness the host's own antiviral defenses.

The virus also exploits cellular lipid architecture. The life cycle of CCoV is intimately connected to plasma membrane cholesterol. Disruption of lipid rafts via cholesterol depletion with methyl-β-cyclodextrin (MβCD) results in a dose-dependent reduction in virus infectivity, affecting both entry and the production of new viral particles [40]. This dependence on cholesterol-rich microdomains for efficient infection places CCoV within a group of viruses that utilize lipid rafts as platforms for assembly and entry, highlighting a potential target for antiviral strategies that interfere with host lipid metabolism.

Evasion of Innate Immunity and Cellular Stress Responses

CCoV has evolved strategies to circumvent the host's intrinsic antiviral defenses. The induction of heme oxygenase-1 (HO-1), a cytoprotective enzyme with antioxidant and anti-apoptotic properties, represents a host countermeasure that CCoV must overcome. HO-1 overexpression, achieved via hemin treatment or plasmid transfection, effectively suppresses CCoV replication in A72 and MDCK cells [25]. The antiviral effect of HO-1 is mediated not only through its enzymatic degradation of pro-oxidant heme but also through the modulation of interferon-related pathways [25]. Exogenous treatment with purified recombinant canine HO-1 protein also inhibits viral protein expression, suggesting a potential therapeutic avenue [25]. However, the fact that CCoV can replicate efficiently in vitro indicates it may have mechanisms to counteract or evade the HO-1-mediated antiviral state.

Viral infection also impacts the biogenesis and composition of extracellular vesicles (EVs). CCoV infection of CRFK cells alters the size, yield, and protein cargo of secreted EVs [30]. These infection-derived EVs carry altered levels of immunomodulatory molecules, including ACE-2, annexin-V, TLR-7, TNF-α, and caspases, compared to EVs from uninfected cells [23, 30]. This hijacking of the host exosomal pathway is hypothesized to facilitate intercellular communication that may promote viral spread, modulate the immune microenvironment, or contribute to the pathogenesis of systemic disease. The specific alterations in EV cargo could serve as biomarkers for infection or as vehicles for delivering viral antigens and immune modulators to distal sites, a mechanism that warrants further investigation.

Systemic Dissemination and Pantropic Pathogenesis

While most CCoV infections are confined to the gastrointestinal tract, the emergence of pantropic CCoV (pCCoV) strains represents a quantum leap in pathogenic potential. These strains, predominantly of the CCoV-IIa subtype, possess the capacity to breach the enteric barrier and disseminate to internal organs including the lungs, liver, spleen, kidneys, and brain [19, 32, 38]. The molecular determinants of this tropism switch are not fully defined but are strongly linked to the S protein and the accessory ORF3abc gene products. Sequence analysis of a pantropic CCoV strain from Italy demonstrated that these viruses can be detected in the internal organs of dogs, often in the absence of significant enteric disease, and are associated with fatal systemic illness [38]. The recombination event that generated a highly pathogenic FCoV-CCoV recombinant responsible for a feline infectious peritonitis (FIP) outbreak in Cyprus involved a minor recombinant region spanning the S gene, showing 96.5% identity to the pantropic canine coronavirus NA/09 [32]. This suggests that small genetic changes, particularly within the S gene, can dramatically alter cell tropism and tissue distribution. A near cat-specific deletion in the domain 0 of the S protein was present in over 90% of FIP cases from this outbreak, implying that this deletion is crucial for a biotype switch towards systemic pathogenicity [32].

The ability to replicate in macrophages is a hallmark of pantropic and highly pathogenic CCoV strains. Isolates such as HLJ-071 and HLJ-073, which are FCoV-like recombinants, can effectively replicate in canine macrophages/monocytes and even in human THP-1 cells [16, 39]. This macrophage tropism is likely a key driver of systemic dissemination, as infected monocytes can carry the virus throughout the body via the bloodstream. Infection of canine monocyte-derived macrophages with pantropic CCoV polarizes these cells towards a classically activated M1 phenotype, characterized by an amoeboid morphology with numerous cytoplasmic processes [33]. However, this activation is dysfunctional, as infected M1 macrophages exhibit reduced phagocytic capacity [33]. This impairment of a critical innate immune function may facilitate secondary bacterial infections and contribute to the severe pathology often observed with pantropic strains. Additionally, severe lymphopenia and immunosuppression are noted in affected animals, compounding the disease outcome [36, 37].

Co-infection Dynamics and the Role of Viral 'Mixing Vessels'

The molecular pathogenesis of CCoV is profoundly influenced by co-infections with other pathogens. Mixed infections with canine parvovirus type 2 (CPV-2), canine adenovirus type 1 (CAV-1), canine distemper virus (CDV), and other enteric viruses are exceedingly common and dramatically exacerbate clinical disease [4, 8, 10, 28, 37]. In a mouse model, CCoV infection induced severe histopathological changes in the liver and lungs, including hemorrhage, lymphocyte infiltration, and glycogen accumulation, which were ameliorated by probiotic administration [36]. These findings highlight that the full pathogenic picture of CCoV is often a product of synergistic interactions with other pathogens.

Furthermore, co-infection within a single host is the engine of CCoV evolution. The simultaneous presence of CCoV-I, CCoV-IIa, and CCoV-IIb, or co-infection with FCoV, provides the raw material for homologous recombination, a frequent and powerful driver of genetic diversity in coronaviruses [1, 6, 24, 29, 32]. The detection of CCoV-2 in captive snow leopards at the Bronx Zoo underscores the role of felids as potential mixing vessels for alphacoronaviruses, where co-infection with both CCoV and FCoV could lead to the emergence of novel recombinants [3]. The high sequence identity (>95.7%) between snow leopard APN and domestic cat APN provides the molecular basis for this susceptibility [3]. The ripple effects of these recombination events are profound, leading to the emergence of viruses like CCoV-HuPn-2018 with zoonotic potential, demonstrating that the molecular pathogenesis of CCoV is inextricably linked to its ecological and evolutionary context. The virus's high genetic plasticity, coupled with its wide host range among carnivores [1, 7, 19, 20], positions it as a significant model for understanding coronavirus emergence and a pathogen that demands continuous molecular surveillance, a point strongly emphasized by the World Health Organization (WHO) in its calls for a One Health approach to emerging infectious diseases.

Epidemiology and Genetic Diversity of Canine Coronavirus

Canine coronavirus (CCoV), a ubiquitous and highly contagious enteric pathogen within the Alphacoronavirus genus, represents a paradigm of viral plasticity and emerging disease risk. Its epidemiology is characterized by a global distribution, high prevalence rates in certain populations, and a complex genetic landscape that is continually reshaped by mutation, recombination, and selective pressures. The virus is not merely an agent of mild, self-limiting gastroenteritis; rather, it serves as a model for understanding coronavirus evolution, cross-species transmission, and the potential for zoonotic spillover. The World Organisation for Animal Health (WOAH) recognizes CCoV as a significant pathogen of canids, and its recent identification in human clinical cases has elevated its status from a routine veterinary concern to a pathogen of potential public health importance, warranting enhanced global surveillance.

Global Prevalence and Risk Factors

The prevalence of CCoV infection in domestic dog populations is substantial and varies considerably by geographic region, diagnostic methodology, and the specific population sampled. A comprehensive systematic review and meta-analysis of studies conducted across mainland China, encompassing over 21,000 samples, estimated a pooled CCoV prevalence of 30% [47]. This figure aligns with earlier estimates from the same region, which reported a pooled prevalence of 33% [44], underscoring the virus's endemicity. However, prevalence can fluctuate dramatically. In northeastern China, a study from 2019-2021 reported a positivity rate of 17.5% [8], whereas in southern China (Guangxi Province), a rate of 8.43% was observed between 2021 and 2024 [4]. This variation is not limited to Asia. In southern Italy, a serological survey of hunting and outdoor dogs revealed a seroprevalence of 53.9%, with molecular detection of active infection in 5.8% of fecal samples [52]. In Turkey, a study in shelter dogs with diarrhea found a striking 38% positivity rate by RT-PCR, with puppies (73.91%) far more likely to be positive than adults (31.50%) [41]. Similarly, in Baghdad and Wasit provinces of Iraq, a 13.5% molecular prevalence was reported in dogs with gastrointestinal issues [42]. These data collectively indicate that CCoV is a persistent and pervasive threat to canine health globally.

Several intrinsic and extrinsic risk factors have been robustly associated with CCoV infection. Age is the most consistently identified factor. Numerous studies document a significantly higher prevalence in young dogs, particularly puppies under six months of age [37, 43, 44, 51]. This is attributed to the immaturity of their adaptive immune system and the waning of maternally derived antibodies. For instance, one investigation in Turkey documented that dogs under one year of age had a 2.375-fold higher odds of infection compared to adults [43]. Seasonality also plays a role, with some research indicating higher infection rates during the winter and spring months, potentially related to increased indoor crowding and environmental stability of the virus [4, 49]. Housing conditions are a critical determinant. Dogs in multi-dog environments, such as shelters, breeding kennels, and pet stores, experience far higher rates of infection due to dense populations, stress-induced immunosuppression, and fecal-oral contamination. In a Turkish shelter, the high prevalence of 38% was directly linked to overcrowding [41]. Co-infections are a hallmark of CCoV epidemiology. A very high proportion of CCoV-positive animals are found to be co-infected with other enteric pathogens, most notably canine parvovirus type 2 (CPV-2), but also canine kobuvirus, canine astrovirus, and canine distemper virus [2, 8, 11, 28, 51]. In one study from Haryana, India, 50% of diarrheic dogs were positive for CPV, and among those, co-infection with CCoV was common [50]. These mixed infections often exacerbate clinical disease severity, leading to more profound gastroenteritis and higher mortality.

Genetic Diversity: Genotypes, Subtypes, and Recombinants

The genetic diversity of CCoV is a direct consequence of its RNA genome's high error rate during replication and its propensity for homologous recombination. The current taxonomic framework delineates two major genotypes, CCoV type I (CCoV-I) and CCoV type II (CCoV-II), which share up to 96% nucleotide identity across the genome but are highly divergent in the spike (S) glycoprotein gene [6]. Within CCoV-II, a further subdivision has been established: the classical CCoV-IIa subtype and the TGEV-like CCoV-IIb subtype, which arose from a double recombination event with porcine transmissible gastroenteritis virus (TGEV) [6]. This classification is not static; the continuous discovery of novel recombinants challenges the boundaries of these groups.

The global distribution of these genotypes is heterogeneous. While CCoV-I was once considered less prevalent, recent molecular surveys have demonstrated its widespread circulation. In Turkey, CCoV-I accounted for nearly 90% of infections in a diarrheic shelter population [41]. In Chengdu, China, a study from 2020-2021 detected CCoV-I in 40 of 59 positive samples, far outnumbering CCoV-IIa (25/59) and CCoV-IIb (1/59) [45]. Conversely, in southern Italy, CCoV-I and CCoV-IIa were detected at similar frequencies (51.3% and 20.5%, respectively), with CCoV-IIb notably absent [2]. In northeastern China, CCoV-II has been historically dominant, with CCoV-IIa being the most prevalent subtype [51]. A study in Guangxi, China, from 2021-2024 identified all 65 sequenced strains as CCoV-II, with 56 belonging to CCoV-IIa and 9 to CCoV-IIb [4]. This geographical and temporal variation suggests that different genotypes may be subject to distinct ecological and immunological pressures.

Recombination is the dominant engine of CCoV genetic diversification and the emergence of novel pathogenic variants. This process is facilitated by the virus's ability to superinfect cells, allowing co-packaging and template-switching during RNA replication. The identification of recombinants is a recurring theme in the literature. A critical event was the emergence of CCoV-IIb, which originated from a recombination between a classical CCoV-II and TGEV, acquiring the TGEV-like S gene [6]. More recently, a study in Yulin, China, detected two significant recombination events among circulating strains [24]. An analysis of CCoV strains from Guangxi Province between 2021 and 2024 identified two recombinant strains (GXBSHM0328-34 and GXYLAC0318-35) with recombination signals in the S gene [4]. In the UK, a major gastroenteritis outbreak in 2022 was linked to a new CCoV variant that harbored an additional spike gene recombination event compared to a 2020 variant, highlighting how recombination drives population-level adaptation and emergence [46, 53]. The biological significance of these events is profound, as recombination can alter receptor binding, tissue tropism, and antigenicity, potentially allowing the virus to evade pre-existing immunity.

Emerging Variants, Pantropic Strains, and Pathogenic Potential

Beyond the standard enteric biotype, the last two decades have witnessed the emergence of highly virulent CCoV variants capable of causing systemic, often fatal disease. These pantropic CCoVs (pCCoVs) are characterized by their ability to escape the gastrointestinal tract and replicate in multiple internal organs, including the spleen, liver, lungs, and lymph nodes. The prototype strain, CB/05, was first identified in Italy, and subsequent surveillance has confirmed the circulation of pantropic CCoV-IIa strains in Italy from 2014-2017, including in dogs imported from Eastern Europe [38]. The genetic determinants of pantropism are not fully defined but are thought to involve specific mutations in the spike protein that alter its interaction with host cell receptors, such as aminopeptidase N (APN), or affect furin cleavage efficiency [13]. The clinical impact is devastating; these strains can cause severe lymphopenia, hemorrhagic gastroenteritis, and high mortality, particularly in young dogs [18].

The host range of these virulent variants extends beyond domestic dogs. Pantropic CCoV has been detected in a wild Italian wolf (Canis lupus italicus) co-infected with CPV and canine adenovirus [19]. More alarmingly, an outbreak of fatal enteritis in captive bush dogs (Speothos venaticus) at UK zoos was attributed to CCoV-IIa, demonstrating that adult animals of highly susceptible species can succumb to infection [18]. The virus has also been identified in red foxes in Hungary, where metagenomic sequencing revealed near-complete CCoV genomes, along with canine circovirus and picodicistrovirus, suggesting frequent virus transmission events among wild carnivores [1]. A novel CCoV, named VuCCoV, caused a massive outbreak of acute diarrhea in farmed foxes in China from 2019 to 2022, resulting in over 39,600 deaths. Its spike protein showed significant divergence from other CCoVs, and its genome contained an ORF3 gene previously only found in CCoV-I, underscoring the virus's adaptive capacity in novel hosts [7]. Most recently, CCoV RNA has been detected in an Amur tiger in China, further expanding the known host range of this virus [20]. These findings, together with the demonstration that CCoV can infect snow leopards, felids that may act as mixing vessels for recombinant alphacoronaviruses [3], paint a picture of a highly transmissible pathogen with a broad and expanding host range.

The Zoonotic Frontier: Canine-Human Recombinants

Perhaps the most profound development in CCoV epidemiology is its documented spillover into the human population. The landmark discovery of a novel canine-feline recombinant alphacoronavirus, designated CCoV-HuPn-2018, in nasopharyngeal swabs of children hospitalized with pneumonia in Sarawak, Malaysia, in 2017-2018, shattered the long-held belief that CCoV was an exclusively canine pathogen [9, 48]. Genome sequencing revealed that while the majority of the virus was closely related to a CCoV-II strain (TN-449), its spike protein was a chimera: the S1 domain was derived from a CCoV-I strain (UCD-1), and the S2 domain from a feline coronavirus (FCoV-II WSU 79-1683) [9]. This mosaic structure suggests a complex recombination history involving both canine and feline viruses, likely within a co-infected host. A second, nearly identical virus (HuCCoV_Z19Haiti) was subsequently isolated from a traveler returning from Haiti suffering from fever and malaise, providing further evidence of the virus's circulation in humans [12]. The United States Centers for Disease Control and Prevention (CDC) has formally recognized the potential for animal coronaviruses to cause human disease, and these findings place CCoV under a new, more intense scrutiny.

The molecular mechanisms that enabled this cross-species jump are under intense investigation. Comparative evolutionary analyses of the spike gene of CCoV-HuPn-2018 have revealed evidence for relaxed selection pressure and an increased rate of molecular evolution in the N-terminal domain (0-domain) of the S protein [13]. This domain is critical for sialic acid binding, which is a key determinant of enteric tropism in TGEV. The authors hypothesize that mutations in this region have led to a loss of sialic acid binding and a shift from enteric to respiratory tropism, analogous to the emergence of porcine respiratory coronavirus (PRCV) from TGEV [13]. The presence of positively selected sites within the signal peptide further suggests adaptation to the human host. While in vitro studies demonstrated that CCoV-HuPn-2018 could not replicate in several human lung cell lines (A549, MRC-5) [48], its ability to infect a human patient and cause disease is undeniable. This event underscores the critical need for continuous, One Health-based surveillance of coronaviruses in domestic and wild carnivore populations to detect and mitigate future zoonotic threats.

Clinical Manifestations and Pathological Features of Canine Coronavirus

Canine coronavirus (CCoV), a member of the species Alphacoronavirus 1 within the family Coronaviridae, presents a remarkably heterogeneous clinical and pathological landscape that extends far beyond the traditional view of a benign, self-limiting enteric pathogen of puppies [6, 21]. The clinical manifestations and underlying pathological features of CCoV infection are dictated by a complex interplay of viral genotype, host immune status, age, concurrent infections, and the emergence of novel recombinant strains with altered tropism. The virus’s high mutation rate and propensity for recombination have yielded variants capable of inducing systemic, often fatal disease, and have even raised significant public health concerns regarding zoonotic spillover, a fact acknowledged by global health authorities such as the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) in the context of emerging coronaviruses [6, 9, 14].

### Classic Enteric Form: Clinical Signs and Course

The archetypal manifestation of CCoV infection is acute gastroenteritis, primarily affecting puppies and immunologically naïve adult dogs [5, 21, 24]. Following an incubation period of 1–4 days, the clinical syndrome is characterized by the sudden onset of lethargy, anorexia, and depression [5, 21]. Vomiting is a prominent early sign, often observed within the first 24–48 hours, rapidly followed by profuse, watery diarrhea that may progress to a mucoid or hemorrhagic consistency [5, 21, 24, 54]. The diarrhea is typically a hallmark of the disease, resulting from the destruction of mature enterocytes at the tips of the small intestinal villi [57]. Affected animals frequently exhibit signs of abdominal discomfort, and dehydration can develop rapidly, particularly in young puppies (<6 weeks of age), leading to hypovolemic shock and electrolyte imbalances if fluid losses are not adequately replaced [5, 21, 37, 54].

In uncomplicated cases, the clinical course is typically self-limiting, with clinical signs resolving within 7–10 days [5, 21]. However, the disease is seldom encountered as a monoinfection in field conditions [10, 51, 54]. Co-infections with other enteric pathogens, most notably canine parvovirus type 2 (CPV-2), but also canine distemper virus (CDV), canine rotavirus (CRV), canine adenovirus type 1 (CAV-1), and canine kobuvirus (CaKV), are extremely common and dramatically exacerbate the severity and duration of clinical signs, often leading to a fatal outcome [2, 8, 10, 28, 37, 50, 51]. Indeed, CCoV-CPV co-infections are frequently associated with a more profound leukopenia, lymphopenia, and hemorrhagic gastroenteritis than infections with either virus alone, significantly increasing mortality rates [11, 37]. The World Organisation for Animal Health (WOAH) recognizes the significant impact of these co-infections on kennel and shelter morbidity and mortality. Epidemiological studies consistently demonstrate that young age, lack of vaccination, and high-density housing (e.g., shelters, breeding kennels) are major risk factors for severe enteric disease [41, 43, 44, 47].

### Pantropic and Highly Virulent Strains: A Systemic Disease

A paradigm shift in our understanding of CCoV pathogenicity occurred with the recognition of pantropic CCoV (pCCoV) strains, primarily of the CCoV-IIa subtype, that are capable of breaching the intestinal epithelial barrier and disseminating to internal organs, including the spleen, liver, lungs, kidneys, and brain [19, 21, 38]. These strains are associated with a severe, systemic, and often fatal disease, particularly in young puppies [18, 38, 60]. Clinical signs extend beyond the gastrointestinal tract and may include profound lethargy, depression, severe anorexia, fever, neurological signs (ataxia, seizures), and respiratory distress [18, 38, 59]. Outbreaks in captive wild canids, such as the bush dog (Speothos venaticus), have demonstrated that adult animals of highly susceptible species can also succumb to the infection, presenting with acute anorexia, severe diarrhea, and rapid progression to death within a few days of clinical onset [18].

The pathology of pCCoV infection is characterized by multiorgan involvement. Gross necropsy findings often include emaciation, severe hemorrhagic and ulcerative enteritis, congested and hemorrhagic mesenteric lymph nodes, splenomegaly, and pulmonary edema or consolidation [18, 59]. Histopathological examination reveals severe viral enteritis with extensive villus blunting, fusion, and crypt epithelial necrosis, accompanied by lymphoid depletion in Peyer's patches, lymph nodes, and spleen [18, 21, 57]. In the lung, lesions consistent with interstitial pneumonia and, in severe cases, acute respiratory distress syndrome (ARDS), have been documented in association with CCoV infection, particularly of the respiratory variant (CRCoV) but also with certain pCCoV strains [18, 59]. The ability of these strains to infect and replicate in macrophages and monocytes is a key determinant of their systemic dissemination and profound immunopathological effects, including the induction of a pro-inflammatory M1 macrophage polarization phenotype, which may contribute to the severity of tissue damage [16, 33, 39].

### Respiratory Coronavirus (CRCoV): A Distinct Clinical Entity

Canine respiratory coronavirus (CRCoV), a distinct betacoronavirus related to bovine coronavirus (BCoV), primarily targets the upper and lower respiratory tract and is a significant component of the canine infectious respiratory disease complex (CIRDC) [55, 56, 58, 59]. CRCoV is highly contagious and exhibits high seroprevalence in dog populations worldwide, particularly in kennels and shelters [52, 58]. Clinically, CRCoV infection is often associated with mild to moderate upper respiratory signs, including a harsh, productive cough, nasal discharge, and occasional sneezing [55, 59]. However, its role as a co-pathogen is critical; CRCoV can predispose the respiratory epithelium to secondary bacterial infections and exacerbate disease caused by other respiratory viruses such as canine influenza virus (CIV), canine distemper virus (CDV), and Bordetella bronchiseptica [49, 58]. In some cases, particularly in young or immunocompromised animals, CRCoV can cause severe bronchointerstitial pneumonia and, rarely, progress to acute respiratory distress syndrome (ARDS) with diffuse alveolar damage, as documented in a fatal case in a previously healthy adult dog [59].

Pathologically, CRCoV targets the ciliated epithelial cells of the trachea and bronchi, leading to ciliary loss, epithelial necrosis, and mucopurulent inflammation [55]. In more severe cases, thickening of the alveolar septa, infiltration of mononuclear cells, and hyaline membrane formation indicative of ARDS are observed [59]. The genetic evolution of CRCoV is ongoing, with recent isolates from China showing unique amino acid mutations in the hemagglutinin-esterase (HE) protein that may enhance receptor-binding affinity, potentially influencing virulence and tissue tropism [55].

### Zoonotic and Emerging Strains: Expanding the Pathological Spectrum

The detection of a novel canine-feline recombinant alphacoronavirus (CCoV-HuPn-2018) in nasopharyngeal swabs from children hospitalized with pneumonia in Malaysia in 2017–2018 marked a watershed moment for CCoV research, demonstrating its previously underestimated zoonotic potential [6, 9, 14, 15]. A subsequent isolation of a nearly identical recombinant virus from a traveler returning from Haiti further confirmed the circulation of these viruses and the risk of human infection across multiple geographic locations [12, 14]. Critically, these strains are not merely enteric; they have been isolated from the respiratory tract of human patients, suggesting a primary respiratory tropism in the human host [9, 13, 48]. The CCoV-HuPn-2018 spike protein shows evidence of relaxed selection in the N-terminal domain (0-domain) responsible for sialic acid binding, a loss-of-function change that is hypothesized to have facilitated a shift from enteric to respiratory tropism, analogous to the evolution of porcine respiratory coronavirus (PRCV) from transmissible gastroenteritis virus (TGEV) [13, 15]. This finding has profound implications, suggesting that the CCoV genome is highly malleable and capable of generating variants with unpredictable tropisms and pathogenic potential, underscoring a significant and ongoing threat to public health.

The pathological spectrum of CCoV is further widened by its capacity to infect an expanding range of host species beyond domestic dogs. Outbreaks of fatal diarrhea due to pantropic CCoV have been documented in bush dogs [18], and CCoV has been implicated in severe enteritis in red foxes (Vulpes vulpes) [1, 7, 11]. Notably, a highly pathogenic canine-feline recombinant coronavirus was responsible for a devastating outbreak of feline infectious peritonitis (FIP) in Cyprus, demonstrating its ability to cause severe systemic disease in cats [32]. Furthermore, molecular evidence of CCoV infection has been detected in captive snow leopards (Panthera uncia) and an Amur tiger (Panthera tigris altaica), indicating that these large felids are also susceptible and may act as mixing vessels for the emergence of new recombinant variants [3, 20]. This expanding host range, coupled with the inherent genetic plasticity of the virus, necessitates continuous global surveillance and a re-evaluation of CCoV as a dynamic and significant pathogen at the animal-human-ecosystem interface.

Diagnostic Approaches for Canine Coronavirus Detection

The accurate and timely diagnosis of canine coronavirus (CCoV) infection is a multifaceted endeavor, necessitating a strategic combination of molecular, serological, virological, and immunological techniques. The diagnostic landscape has evolved considerably, driven by the need to differentiate between enteric and respiratory biotypes, identify emerging recombinant strains with zoonotic potential, and manage co-infections that complicate clinical presentations. A comprehensive diagnostic approach must account for the virus's genetic diversity, its variable tissue tropism, and the dynamic nature of the host immune response. This section provides an exhaustive analysis of the contemporary diagnostic armamentarium for CCoV, integrating insights from the most recent research to inform best practices in clinical and research settings.

Molecular Detection: The Gold Standard for Active Infection

Molecular methods, particularly reverse transcription polymerase chain reaction (RT-PCR) and its quantitative variants (RT-qPCR), constitute the cornerstone of active CCoV detection due to their unparalleled sensitivity, specificity, and rapid turnaround time. These techniques target conserved regions of the viral genome, most commonly the membrane (M) gene, the nucleocapsid (N) gene, or the spike (S) gene, enabling detection across diverse genotypes and subtypes.

Conventional and Quantitative RT-PCR

Conventional RT-PCR remains a widely used tool for initial screening and genotyping. Studies have demonstrated its utility in detecting CCoV in fecal samples, with reported prevalence rates varying significantly by geographic region and population. For instance, in a study of diarrheic shelter dogs in Sivas, Türkiye, RT-PCR targeting the M gene revealed an overall positivity rate of 38% (57/150), with a striking 73.91% positivity in puppies compared to 31.50% in adults [41]. This technique also facilitates genotyping; the same study successfully differentiated CCoV Type I (89.47%) from CCoV Type II (10.53%) using a second primer set based on the M gene [41]. Similarly, investigations in Iraq and China have employed RT-PCR to identify CCoV-II as the predominant circulating genotype, with prevalence rates of 13.5% and 14.2%, respectively [24, 42]. The utility of conventional PCR extends to detecting viral RNA in various sample types, including spleen tissue, as demonstrated in a metatranscriptomic study of dogs in Yulin, China, which confirmed CCoV presence and identified two co-circulating genotypes [24].

Quantitative RT-PCR (RT-qPCR) offers significant advantages over conventional PCR, including the ability to quantify viral load, which can be correlated with disease severity and prognosis. The development of multiplex RT-qPCR assays has been a major advancement, allowing for the simultaneous detection of CCoV alongside other common canine enteric or respiratory pathogens. A notable example is the quadruplex RT-qPCR developed by Shi et al. (2024), which simultaneously detects CCoV (M gene), canine respiratory coronavirus (CRCoV; N gene), canine adenovirus type 2 (CAV-2; hexon gene), and canine norovirus (CNV; RdRp gene) [61]. This assay demonstrated exceptional performance characteristics, with limits of detection (LOD) of 1.0 × 10² copies/reaction for each target, no cross-reactivity with other canine viruses, and excellent repeatability (intra-assay variability 0.19–1.31%; inter-assay variability 0.10–0.88%) [61]. Clinical validation on 1,688 samples from Guangxi, China, revealed positivity rates of 8.59% for CCoV, 8.65% for CRCoV, 2.84% for CAV-2, and 1.30% for CNV, with >99.53% agreement with reference assays [61]. Another quadruplex RT-qPCR, designed to detect CCoV, canine rotavirus (CRV), canine parvovirus (CPV), and canine distemper virus (CDV), achieved LODs of 1.1 × 10² copies/reaction and demonstrated excellent clinical utility on 1,028 samples, with CCoV positivity of 9.53% [28]. These multiplex platforms are invaluable for differential diagnosis, as co-infections are exceedingly common and can exacerbate clinical outcomes [10, 51].

For respiratory pathogens, a Taqman probe-based multiplex real-time PCR has been developed to detect CRCoV alongside canine influenza virus (CIV), CDV, and canine parainfluenza virus (CPiV) [56]. This assay targets the M gene of CRCoV and CIV, the N gene of CDV, and the NP gene of CPiV, achieving LODs of 10 copies/μL for CIV and CRCoV and 100 copies/μL for CDV and CPiV [56]. The high sensitivity and specificity of these molecular tools are critical for early detection and containment, particularly in kennel environments where respiratory disease complexes are prevalent.

One-Step and Direct PCR Methods

Innovations in PCR technology have streamlined the diagnostic workflow. A one-step duplex PCR (one-step dPCR) assay for simultaneous detection of CDV and CCoV eliminates the nucleic acid extraction step, allowing samples to be added directly to the PCR reagents [69]. This approach significantly reduces processing time and the risk of contamination, making it particularly suitable for field diagnostics and resource-limited settings. The assay, targeting the H gene of CDV and the M gene of CCoV, demonstrated high specificity and sensitivity, with results verified by independent sequencing [69].

Considerations for Molecular Diagnostics

Despite their power, molecular methods have limitations. The high genetic diversity of CCoV, driven by mutation and recombination, can lead to false negatives if primers are not designed against conserved regions. The emergence of novel recombinant strains, such as the pantropic CCoV-IIa variants and the canine-feline recombinant CCoV-HuPn-2018, underscores the need for continuous surveillance and primer redesign [6, 9, 10]. Furthermore, the detection of viral RNA does not necessarily indicate the presence of infectious virus, as RNA can persist in the environment or in samples after the resolution of clinical signs. Therefore, molecular results should always be interpreted in conjunction with clinical history and, where possible, confirmed by virus isolation or serological testing.

Serological Assays: Detecting Past Exposure and Immune Status

Serological testing provides critical information regarding past exposure, immune status, and vaccine efficacy. These assays detect antibodies (primarily IgG) against CCoV in serum or plasma, offering a window into the population-level epidemiology of the virus.

Enzyme-Linked Immunosorbent Assay (ELISA)

ELISA is the most commonly employed serological method due to its high throughput, objectivity, and quantitative nature. Commercial ELISA kits are widely available for detecting antibodies against CCoV. A study in southern Italy utilized a commercial ELISA to determine a seroprevalence of 53.9% (139/258) among dogs, with multivariate analysis identifying hunting dogs and those with an outdoor lifestyle as having significantly higher odds of seropositivity [52]. This highlights the utility of serology in identifying risk factors for exposure.

The development of recombinant antigen-based ELISAs has enhanced specificity and reduced reliance on whole-virus preparations. Hao et al. (2021) developed an indirect ELISA using a multiepitope recombinant S protein (rSP) as the coating antigen [65]. This rSP was designed by arranging four S fragments and two T-cell epitopes in tandem, resulting in a 25 kDa protein that was specifically recognized by CCoV-positive sera. The assay showed no cross-reactivity with antisera against CDV, CPV, or feline calicivirus, and demonstrated a positive rate of 82.8% when testing 64 clinical serum samples [65]. The identification of a novel linear B cell epitope (EP-13E8) within the N protein, which is 100% conserved among different CCoV strains, provides another promising target for developing epitope-based serological diagnostics [62]. Monoclonal antibodies against such conserved epitopes could form the basis for highly specific and sensitive diagnostic kits.

Virus Neutralization (VN) Test

The VN test remains the gold standard for assessing functional antibody responses, as it measures the ability of antibodies to neutralize viral infectivity. This test is particularly important for evaluating vaccine efficacy and for seroepidemiological studies. In a study of Vietnamese dogs, the VN test revealed a seroprevalence of 43.3% (87/201) against CCoV-II [70]. The VN test can also differentiate between antigenic subtypes; the same study demonstrated that the antigenicity of a CCoV-IIb isolate was equal to or higher than that of a CCoV-IIa isolate [70]. However, the VN test is labor-intensive, requires cell culture facilities, and takes several days to complete, limiting its use in routine clinical practice.

Hemagglutination Inhibition (HI) Test

The HI test offers a simpler and faster alternative to the VN test for detecting antibodies against CRCoV. A study evaluating the HI test for CRCoV found a strong correlation with the VN test (R = 0.83, p < 0.001), validating its use as a surrogate [67]. Using the HI test, a seroprevalence of 52.2% was determined among 383 Korean dogs, with significantly higher positivity in dogs aged 3-5 years (66.7%) compared to those under 1 year (43.9%) [67]. The HI test is particularly advantageous because it does not require live virus or cell culture, making it more accessible for large-scale surveillance.

Rapid Diagnostic Tests (RDTs): Point-of-Care Solutions

Rapid diagnostic tests, typically based on lateral flow immunochromatography, provide a practical solution for point-of-care (POC) testing in veterinary clinics. These tests detect viral antigens in fecal or nasal swab samples and deliver results within 10-20 minutes, enabling immediate clinical decision-making.

Performance Characteristics of RDTs

A commercially available lateral flow test kit for CCoV antigen detection was evaluated by Yoon et al. (2018), demonstrating a clinical sensitivity of 93.1% and a specificity of 97.5% compared to PCR [68]. The detection limit was between 1.97 × 10⁴ and 9.85 × 10³ TCID₅₀/mL, and the test showed no cross-reactivity with CPV, CDV, or Escherichia coli [68]. These performance metrics are acceptable for a screening test, particularly in settings where PCR is not readily available. However, a comparative study in Egypt found that the sensitivity of immunochromatography (IC) was only 71% compared to RT-qPCR, with a specificity of 100% [66]. This lower sensitivity suggests that RDTs may miss a significant proportion of infections, especially those with low viral loads. Therefore, a negative RDT result should be confirmed by a more sensitive molecular method if clinical suspicion remains high.

Multiplex Antigen Detection

The development of double-labeling time-resolved fluorescence immunoassay (TRFIA) kits represents a significant advancement in POC diagnostics. Li et al. (2024) developed a TRFIA kit for the simultaneous detection of CCoV and CPV-2 using europium(III) and samarium(III) chelates [63]. This sandwich assay demonstrated high sensitivity (0.51 ng/mL for CCoV, 0.80 ng/mL for CPV-2), excellent specificity, and good stability (12 months at -20°C). Clinical evaluation on 137 samples showed no statistically significant difference compared to PCR, with clinical sensitivity and specificity of 95.74% and 93.33% for CCoV, respectively [63]. The TRFIA technology offers the advantages of quantitative results, multiplexing capability, and reduced background fluorescence, making it a powerful tool for clinical diagnostics.

Virus Isolation and Cell Culture: The Definitive Diagnostic Method

Virus isolation remains the definitive method for confirming the presence of infectious virus and is essential for downstream applications such as genomic characterization, pathogenesis studies, and vaccine development. However, it is time-consuming, technically demanding, and requires specialized biosafety facilities.

Cell Line Susceptibility

The success of virus isolation depends critically on the choice of cell line. The A-72 canine fibrosarcoma cell line is the most commonly used and is highly permissive for CCoV infection, including the novel recombinant CCoV-HuPn-2018 [9, 48]. Other cell lines, including Madin-Darby canine kidney (MDCK), Crandell-Rees feline kidney (CRFK), and SPEV cells, have also been used with variable success [48, 64]. A comparative study by Radzyhovskyi et al. (2024) found that BHK-21 cells exhibited the most intensive cytopathogenic effect (CPE), with 90-100% cell destruction observed within 5-6 days post-infection, and the infectious titer increased with each passage, reaching 4.8 ± 0.04 lg TCID₅₀/cm³ by the fifth passage [64]. In contrast, human lung cell lines (A549, MRC-5) and other animal cell lines (VeroE6, ST, Mv1Lu) are not permissive for CCoV-HuPn-2018, suggesting a narrow host range in vitro that may not fully recapitulate in vivo tropism [48].

Cytopathogenic Effect and Confirmation

Infected cells typically exhibit characteristic CPE, including rounding, detachment, and syncytia formation, which can be observed within 48 hours post-infection [64]. Confirmation of CCoV identity is achieved through immunofluorescence, electron microscopy, or RT-PCR. Electron microscopy reveals typical coronavirus particles (80-120 nm in diameter) with characteristic club-shaped spikes [17]. The use of ultrafiltration methods can enhance viral titers from cell culture supernatants, although the gain for enveloped viruses like CCoV may be less than for non-enveloped viruses [71].

Advanced and Emerging Diagnostic Technologies

Metagenomic Next-Generation Sequencing (mNGS)

Metagenomic next-generation sequencing (mNGS) has emerged as a powerful, unbiased tool for pathogen discovery and characterization. This approach allows for the simultaneous detection of all nucleic acids in a sample, enabling the identification of novel or unexpected pathogens without a priori knowledge. mNGS has been instrumental in identifying recombinant CCoV strains in red foxes [1], characterizing a novel CCoV causing diarrhea in foxes (VuCCoV) [7], and confirming the presence of CRCoV in a dog with acute respiratory distress syndrome (ARDS) [59]. The utility of mNGS in clinical diagnostics is demonstrated by its ability to provide a complete viral genome sequence, which is critical for understanding recombination events, tracking transmission chains, and assessing zoonotic risk [59]. As costs decrease and bioinformatics pipelines improve, mNGS is poised to become a standard tool for complex or atypical cases.

Extracellular Vesicle (EV) Analysis

Emerging research suggests that CCoV infection modulates the biogenesis and composition of host-derived extracellular vesicles (EVs) [23, 30]. EVs isolated from infected cells show altered expression of proteins such as ACE-2, annexin-V, flotillin-1, and various cytokines [30]. These virus-modified EVs may play a role in intercellular communication, immune modulation, and viral dissemination. While not yet a routine diagnostic tool, the analysis of EV cargo could provide novel biomarkers for infection severity, prognosis, and therapeutic response. The study of EVs also offers a window into the mechanisms of viral pathogenesis and the host-pathogen interface [23].

Diagnostic Algorithm and Best Practices

A rational diagnostic approach for CCoV should be guided by the clinical presentation, epidemiological context, and available resources.

1. Initial Screening (Point-of-Care): For a dog presenting with acute gastroenteritis or respiratory signs, a rapid antigen test (lateral flow or TRFIA) on a fecal or nasal swab can provide immediate results. A positive result in a clinically compatible case is highly suggestive of CCoV infection. A negative result, however, does not rule out infection, particularly if clinical signs are severe or if the sample was collected late in the disease course.

2. Confirmatory Testing (Molecular): All negative RDT results from clinically suspicious cases should be confirmed by RT-PCR or RT-qPCR. Multiplex assays are preferred to simultaneously rule out other common pathogens (e.g., CPV, CDV, CRCoV, CAV-2). Quantitative RT-PCR can provide viral load data, which may have prognostic value.

3. Genotyping and Surveillance: For epidemiological surveillance, outbreak investigations, or cases with unusual clinical features (e.g., systemic disease, high mortality), genotyping by sequencing the S, M, or N genes is recommended. This is essential for identifying emerging variants, recombinant strains, and potential zoonotic threats. Phylogenetic analysis can trace the origin and spread of specific strains [2, 4, 24, 41].

4. Serological Testing: Serology is not useful for diagnosing acute infection due to the time required for seroconversion. However, it is valuable for:

   • Seroepidemiological studies: To determine population-level exposure and identify risk factors.
   • Vaccine efficacy assessment: To measure neutralizing antibody titers post-vaccination.
   • Diagnosis of past infection: A four-fold rise in antibody titers between acute and convalescent sera can confirm recent infection.

5. Virus Isolation: This is reserved for research purposes, such as characterizing new strains, developing vaccines, or studying viral pathogenesis. It is not recommended for routine clinical diagnosis.

Conclusion of Diagnostic Approaches

The diagnosis of canine coronavirus infection has advanced from reliance on clinical signs and virus isolation to a sophisticated array of molecular, serological, and point-of-care technologies. The selection of the appropriate diagnostic test depends on the specific clinical question: rapid antigen tests for immediate clinical decisions, RT-qPCR for sensitive and specific detection of active infection, sequencing for genotyping and surveillance, and serology for population-level studies. The continuous evolution of CCoV, driven by mutation and recombination, necessitates ongoing surveillance and the periodic re-evaluation of diagnostic targets to ensure that tests remain effective against circulating strains. The integration of these diverse diagnostic modalities, guided by a clear understanding of their strengths and limitations, is essential for the effective management, control, and prevention of CCoV infection in canine populations and for monitoring its potential threat to public health.

Interspecies Transmission and Zoonotic Potential of CCoV

The perception of canine coronavirus (CCoV) as a pathogen of strictly veterinary concern has been fundamentally challenged by a growing body of evidence demonstrating its capacity for cross-species transmission and, most alarmingly, its emergence as a zoonotic agent. Historically classified as an enteric pathogen of canids, CCoV has exhibited a remarkable genetic plasticity that facilitates host range expansion, recombination with coronaviruses of other species, and adaptation to human hosts. The implications of these findings are profound, necessitating a re-evaluation of CCoV within the framework of One Health and pandemic preparedness.

The Definitive Evidence for Zoonotic Spillover: CCoV-HuPn-2018 and Related Strains

The most compelling evidence for the zoonotic potential of CCoV emerged from a landmark study conducted in Sarawak, Malaysia, where a novel canine-feline recombinant alphacoronavirus, designated CCoV-HuPn-2018, was isolated from a pediatric pneumonia patient [9]. This discovery was not an isolated incident; the virus was detected in nasopharyngeal swabs from eight (2.5%) of 301 patients hospitalized with pneumonia during 2017–2018, with most affected being children living in rural areas with frequent exposure to domesticated animals and wildlife [9]. The complete genome sequencing of the isolate revealed a complex recombinant structure: the majority of its genome was closely related to a CCoV TN-449 strain, while its spike (S) gene exhibited significantly higher sequence identity with CCoV-UCD-1 in the S1 domain and a feline coronavirus (FCoV) WSU 79-1683 in the S2 domain [9]. This chimeric architecture underscores the critical role of recombination in generating viruses with novel tropisms capable of breaching species barriers.

The public health significance of this finding was amplified by the subsequent isolation of a nearly identical virus, HuCCoV_Z19Haiti, from a medical team member presenting with fever and malaise after travel to Haiti [12]. This virus shared 99.4% similarity with the Malaysian strain, demonstrating that infection with this recombinant lineage is not a geographically restricted phenomenon but occurs in multiple locations [12]. The World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) have acknowledged the emergence of such animal-origin coronaviruses as a persistent threat, and these cases represent the first documented instances of a CCoV-related virus causing clinical disease in humans. If confirmed as a bona fide human pathogen, CCoV-HuPn-2018 would constitute the eighth unique coronavirus known to cause disease in humans, joining the ranks of HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1, SARS-CoV, MERS-CoV, and SARS-CoV-2 [9, 15].

Molecular Mechanisms Facilitating Cross-Species Transmission

The capacity of CCoV to jump species is rooted in its fundamental virological properties, particularly its high mutation rate and propensity for recombination. As an RNA virus, CCoV lacks proofreading mechanisms, leading to a high frequency of genetic variation. However, it is recombination, the exchange of genetic material between co-infecting coronaviruses, that has been the primary driver of the emergence of strains with altered host ranges. The CCoV-HuPn-2018 strain is a prime example, but it is far from unique. Recombination between CCoV and transmissible gastroenteritis virus (TGEV) of swine gave rise to the CCoV-IIb subtype, which possesses a TGEV-like spike gene [6, 15]. Similarly, recombination between CCoV and FCoV has produced highly pathogenic variants, including a strain responsible for a devastating outbreak of feline infectious peritonitis (FIP) in Cyprus, where a minor recombinant region spanning the spike gene showed 96.5% sequence identity to the pantropic canine coronavirus NA/09 [32].

The receptor usage of CCoV is a critical determinant of its host range. Both CCoV type II and FCoV type II utilize aminopeptidase N (APN) as their cellular receptor [3]. The APN molecule is highly conserved across carnivores and even shares significant homology with human APN. This receptor compatibility provides a molecular bridge for cross-species infection. For instance, the receptor-binding domain (RBD) of a raccoon dog-origin CCoV-IIa showed robust binding to raccoon dog APN but not to human APN [11]. However, the spike protein of CCoV-HuPn-2018 has undergone specific adaptations that may alter its receptor interactions. Detailed evolutionary analyses of the spike gene revealed that the N-terminal domain (NTD), or 0-domain, of CCoV-HuPn-2018 has experienced relaxed selection pressure, an increased rate of molecular evolution, and unique amino acid substitutions relative to both CCoV-IIb and TGEV [13]. Critically, a region of the 0-domain known to be key for sialic acid binding and enteric pathogenesis in TGEV showed clear differences in CCoV-HuPn-2018, leading to the hypothesis that the virus has lost its enteric tropism and evolved a respiratory tropism instead, analogous to the porcine respiratory coronavirus (PRCV) [13]. This tropism shift is a hallmark of adaptation to a new host species.

Expanding Host Range: Evidence from Wildlife and Non-Canine Domestic Species

The zoonotic events are the most dramatic examples of CCoV's cross-species capability, but the virus has been documented in a wide and expanding range of non-canine hosts, demonstrating its inherent capacity to infect diverse mammalian species. This broad host range serves as a reservoir for viral evolution and increases the probability of spillover events into humans.

Felids as Mixing Vessels: Domestic and wild felids have emerged as critical hosts in the ecology of CCoV. The APN receptor of domestic cats allows entry of FCoV-II, CCoV-II, and other alphacoronaviruses, making felids potential "mixing vessels" for recombination [3]. This was dramatically illustrated by an outbreak of enteritis in captive snow leopards (Panthera uncia) at the Bronx Zoo, where whole-genome sequencing revealed shedding of CCoV-II in their feces [3]. The strain was related to highly pathogenic variants circulating in the US and Europe, and the snow leopard APN gene showed >95.7% identity to that of the domestic cat [3]. More recently, CCoV RNA was detected in a captive Amur tiger (Panthera tigris altaica) in China, with the viral genome showing evidence of recombination involving strains from other carnivore species [20]. These findings indicate that large felids are susceptible to CCoV infection and may serve as novel hosts for viral evolution.

Wild Canids and Mustelids: The circulation of CCoV in wild carnivore populations is extensive. In Hungary, metagenomic analysis of red foxes (Vulpes vulpes) yielded near-complete genome sequences of CCoV, along with canine circovirus and canine picodicistrovirus, marking the first fox-origin CCoV sequence data [1]. The study suggested that recombination is of great importance in the evolution of CCoV infecting wild-living carnivores, including the red fox and golden jackal [1]. A particularly devastating outbreak occurred in farmed foxes (Vulpes) in Shenyang, China, where a novel CCoV (VuCCoV) caused an epidemic of acute diarrhea resulting in over 39,600 deaths between 2019 and 2022 [7]. The VuCCoV genome shared >90% nucleotide identity with CCoV for three structural genes, but the spike gene showed significant divergence, and the virus's RdRp had only two to three amino acid differences from a bat coronavirus, suggesting a close genetic relationship [7]. This highlights the potential for CCoV to act as a bridge between wildlife reservoirs and domestic animals.

Other documented hosts include bush dogs (Speothos venaticus), where CCoV-IIa caused fatal outbreaks in zoological collections [18]; raccoon dogs (Nyctereutes procyonoides), where CCoV-IIa and IIb subtypes were detected in diarrheic outbreaks [11]; and an Italian wolf (Canis lupus italicus), which was found to be infected with a pantropic CCoV strain [19]. The detection of pantropic CCoV in wolves and its co-circulation with other canine viruses underscores the role of wild carnivores as reservoirs and potential sources of novel variants [19, 38].

The Role of Recombination in Generating Zoonotic Threats

The evidence overwhelmingly points to recombination as the primary engine of CCoV evolution and the key mechanism enabling zoonotic emergence. The CCoV-HuPn-2018 strain is a recombinant of canine and feline coronaviruses [9, 13]. The highly pathogenic FIP outbreak in Cyprus was caused by a FCoV-CCoV recombinant [32]. The CCoV-IIb subtype arose from recombination with TGEV [6]. In China, a novel CCoV strain (HLJ-071) was found to be a recombinant of FCoV 79-1683, FCoV DF2, and CCoV A76, and it could replicate in canine macrophages and human THP-1 cells [16]. Another strain, HLJ-073, with a large deletion in ORF3abc, also originated from recombination between FCoV and CCoV and could replicate in human THP-1 cells [39]. These findings demonstrate that recombination events are not rare anomalies but a frequent and ongoing process that generates viruses with altered cell tropism, including the ability to infect human cells.

The World Organisation for Animal Health (WOAH) recognizes the importance of monitoring such genetic changes in animal coronaviruses, as they can presage the emergence of pathogens with pandemic potential. The high prevalence of CCoV in dog populations worldwide, with pooled prevalence estimates of 30% in China [47] and detection rates of 14-38% in various studies [2, 24, 41], combined with its propensity for recombination, creates a vast evolutionary playground for the generation of novel variants.

Modulating Factors and Future Risks

Several factors may influence the likelihood and severity of future CCoV spillover events. Environmental contaminants, such as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), have been shown to intensify CCoV infection in vitro by modulating the aryl hydrocarbon receptor (AhR) signaling pathway, leading to increased virus yield and enhanced cytopathology [22]. This suggests that environmental pollution could exacerbate viral shedding in animal populations, increasing the infectious pressure on humans. Furthermore, the host immune response plays a critical role. The formyl peptide receptor 2 (FPR2) has been identified as a key modulator of CCoV infection, with its inhibition leading to increased viral replication [26]. Understanding these host-virus interactions is crucial for developing antiviral strategies.

The potential for CCoV to cause human disease extends beyond the documented cases of pneumonia. A systematic review and meta-analysis of CCoV in China noted that CCoV and canine rotavirus are confirmed to have important zoonotic potential and cause public health issues [28]. The serological cross-reactivity between CCoV nucleocapsid proteins and antisera against human coronaviruses (HCoV-229E and NL63) further complicates the diagnostic landscape and suggests that past exposure to animal coronaviruses may influence the human immune response to related viruses [72]. The emergence of a novel CCoV variant associated with severe gastroenteritis in UK dogs in 2022, which was unrelated to the human-associated strains, serves as a reminder that the evolutionary trajectory of CCoV is unpredictable and that continuous surveillance is essential [46, 53]. The Food and Agriculture Organization (FAO) has emphasized the need for integrated surveillance at the animal-human interface, and CCoV represents a clear and present example of why such vigilance is necessary.

Environmental and Immunomodulatory Factors Affecting CCoV Severity

The clinical trajectory of canine coronavirus (CCoV) infection, ranging from subclinical enteritis to fatal systemic disease, is governed not solely by viral genotype but profoundly by the interplay of environmental stressors, xenobiotic exposures, and the host's immunomodulatory milieu. The emergence of highly virulent pantropic strains and recombinant variants capable of crossing species barriers has intensified scrutiny of the factors that potentiate viral replication and exacerbate disease [6, 15]. Emerging evidence indicates that environmental contaminants, particularly persistent organic pollutants such as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), can act as potent immunomodulatory agents that amplify CCoV pathogenesis through specific receptor-mediated signaling pathways. Concurrently, host factors including the aryl hydrocarbon receptor (AhR), formyl peptide receptor 2 (FPR2), heme oxygenase-1 (HO-1), and type III interferons constitute critical determinants of antiviral resilience. This section systematically examines the mechanistic underpinnings by which environmental and immunomodulatory variables modulate CCoV severity, with particular emphasis on receptor-mediated pathways that bridge toxicology and virology.

The Aryl Hydrocarbon Receptor as a Nexus of Environmental Toxicity and Viral Replication

The AhR is a ligand-activated transcription factor that has emerged as a central molecular intersection between environmental contaminant exposure and coronavirus infection dynamics. Canonically recognized for mediating the toxic effects of planar aromatic hydrocarbons, AhR activation has recently been demonstrated to exert profound influences on coronavirus replication. Infection of canine fibrosarcoma (A72) cells with CCoV genotype II results in substantial upregulation of AhR expression, and this activation is functionally linked to viral replication efficiency [34]. Pharmacological inhibition of AhR using the antagonist CH223191 during CCoV infection suppresses cell death, enhances cell viability, and produces a meaningful decline in virus yield accompanied by inhibition of viral nucleocapsid protein (NP) expression [34]. These findings establish AhR as a proviral factor that, when activated, facilitates CCoV replication.

The significance of this pathway is amplified considerably when considering environmental exposure to TCDD, a potent AhR ligand and persistent environmental contaminant. In a landmark in vitro investigation, Sorbo and colleagues (2025) demonstrated that TCDD exposure during CCoV infection induces a substantial dose-dependent increase in virus yield and NP expression [22]. Infected cells exhibited pronounced alterations in cell morphology that were extensively enhanced by TCDD treatment, and these effects were mechanistically linked to modulation of AhR protein levels [22]. This finding carries profound implications for canine populations in industrialized or contaminated environments, where chronic low-level dioxin exposure may create an immunological milieu permissive to severe CCoV disease. The ability of TCDD to intensify CCoV infection through AhR signaling suggests that environmental pollution constitutes an underappreciated risk factor for coronavirus disease severity in dogs, analogous to the relationship between air pollution and COVID-19 severity in humans.

Conversely, natural and synthetic compounds that antagonize AhR signaling demonstrate therapeutic potential. Fungal secondary metabolites, including 6-pentyl-α-pyrone (6 PP) from Trichoderma atroviride and funicone-like compounds such as vermistatin, penisimplicissin, and 3-O-methylfunicone (OMF), have each been shown to reduce CCoV replication in association with marked downregulation of AhR expression [27, 31, 35]. Notably, treatment with 6 PP at non-toxic concentrations significantly increased cell viability, reduced morphological signs of cell death, and inhibited viral replication in vitro [27]. The consistent observation that AhR antagonists suppress CCoV infection while AhR agonists exacerbate it positions this receptor as a critical rheostat of disease severity, modulated by both environmental contaminants and dietary or pharmacological interventions.

Formyl Peptide Receptor 2: A Double-Edged Immunomodulator

The formyl peptide receptor family, particularly FPR2, plays a crucial role in modulating innate immune responses and is variably regulated during viral infections. Giugliano and colleagues (2025) provided compelling evidence that FPR2 expression is actively modulated during CCoV infection in both canine A72 cells and feline CRFK cells [26]. Pharmacological inhibition of FPR2 using the specific antagonist WRW4 resulted in reduced gene and protein levels of FPR2 in infected cells, accompanied by worsened cell viability and morphological changes, substantial increases in virus yield, and significant upregulation of NP gene and protein expression [26]. Conversely, treatment with the FPR2 agonist HP2-20 produced an opposite trend, conferring a protective effect against CCoV replication [26].

The mechanistic basis for these opposing effects was elucidated through in silico modeling of the canine FPR2 (cFPR2) receptor. The antagonist WRW4 was confined to the receptor core without interacting with extramembrane loops, whereas the agonist HP2-20 contacted both the core and the second extracellular loop (ECL2), resulting in a marked increase in hydrogen bonds, hydrophobic interactions, and electrostatic charges [26]. These structural differences likely underpin the divergent functional outcomes. The identification of FPR2 as a determinant of CCoV replication opens avenues for therapeutic targeting, suggesting that FPR2 agonists may represent a novel class of immunomodulatory antivirals. However, the finding that FPR2 inhibition exacerbates infection underscores the delicate balance of innate immune signaling in controlling coronavirus replication.

Heme Oxygenase-1 and the Antiviral Interferon Axis

Heme oxygenase-1 (HO-1), the rate-limiting enzyme in heme degradation, has emerged as a critical immunomodulatory factor with broad-spectrum antiviral properties. Beyond its canonical antioxidant and anti-apoptotic functions, HO-1 exerts antiviral effects through modulation of interferon-related pathways [25]. In the context of CCoV, Kim and colleagues (2025) demonstrated that pharmacological induction of HO-1 using hemin, as well as transient overexpression of recombinant canine HO-1, effectively suppressed CCoV replication in A72 cells [25]. Furthermore, treatment with purified recombinant HO-1 protein reduced viral protein levels following infection, indicating that HO-1's antiviral activity is not dependent on its intracellular enzymatic function alone but can be mediated exogenously [25].

The mechanistic linkage between HO-1 and interferon signaling is particularly relevant to CCoV pathogenesis. HO-1 induction potentiates interferon responses, creating an antiviral state that restricts coronavirus replication. This pathway has been exploited therapeutically through the use of recombinant adenoviruses expressing canine interferon lambda 3 (Ad-caIFNλ3), which effectively suppressed CCoV replication in A72 and MDCK cells without cytotoxicity [75]. The convergence of HO-1 and type III interferon signaling represents a natural host defense mechanism that can be therapeutically augmented. The WOAH recognizes the importance of such innate immune modulators in managing viral diseases of companion animals, particularly in settings where vaccination coverage is incomplete.

Toll-Like Receptor 7 Agonism and MAPK/ERK Signaling

The Toll-like receptor 7 (TLR7) pathway represents another immunomodulatory axis with demonstrated activity against CCoV. Imiquimod, a TLR7 agonist approved for topical use in human medicine, exhibits concentration-dependent antiviral activity against both SARS-CoV-2 and CCoV in epithelial cells, underscoring its broad-spectrum action against coronaviruses [73]. Importantly, the anti-coronavirus effect of imiquimod appears to be independent of the canonical TLR7/NF-κB pathway and the PKA/EPAC pathway, instead operating through activation of the MEK/ERK signaling cascade [73]. This finding has significant implications for therapeutic development, as it identifies a shared signaling vulnerability among diverse coronaviruses that can be targeted by immunomodulatory compounds. The ability of imiquimod to inhibit coronavirus replication via the MEK/ERK pathway, coupled with its established immunomodulatory properties, highlights its potential as a broad-spectrum antiviral for both human and veterinary applications.

Cytokine Milieu and Macrophage Polarization

The balance of pro-inflammatory and anti-inflammatory cytokine responses critically influences CCoV disease severity. Pantropic CCoV strains, which have the capacity to disseminate beyond the gastrointestinal tract to cause systemic and often fatal disease, induce a distinctive immunomodulatory profile in host macrophages. In vitro studies have demonstrated that pantropic CCoV infection of canine peripheral blood monocyte-derived macrophages predominantly polarizes these cells toward the classically activated M1 phenotype, characterized by amoeboid morphology with numerous fibrillary cytoplasmic processes [33]. This M1 polarization was associated with reduced phagocytic activity, as evidenced by decreased neutral red uptake, and with the release of new viral particles at 18 hours post-infection accompanied by a decrease in viable cells [33]. The induction of M1 macrophages by pantropic CCoV suggests that the virus exploits inflammatory signaling to establish systemic infection, while simultaneously impairing the phagocytic clearance mechanisms that would normally contain enteric pathogens.

Cytokine dysregulation is further evidenced by alterations in expression of tumor necrosis factor-alpha (TNF-α), caspase-1, and caspase-8 in extracellular vesicles (EVs) derived from CCoV-infected cells [30]. The modulation of EV biogenesis and cargo composition during CCoV infection represents a sophisticated mechanism by which the virus manipulates the extracellular environment to facilitate viral progression and disease development [23, 30]. EVs from infected cells carry altered levels of ACE-2, annexin-V, flotillin-1, TLR-7, and LAMP, among other proteins, potentially influencing intercellular communication and immune signaling [30]. The WHO has noted that understanding such virus-host interactions at the molecular level is essential for predicting and preventing severe disease outcomes in both animal and human coronavirus infections.

Nutritional Immunomodulation: Probiotics and Colostrum

Dietary interventions that modulate the immune response represent a promising but underutilized strategy for mitigating CCoV severity. Probiotic supplementation with Bifidobacterium and Lactobacillus species has demonstrated beneficial immunomodulatory effects in murine models of CCoV vaccine induction. Hamid and colleagues (2026) reported that probiotic-treated animals exhibited significant improvements in hematological parameters, including leukocyte count, hemoglobin levels, and lymphocyte and neutrophil counts, along with reduced caspase-3 levels and increased interferon-gamma (IFN-γ) expression [76]. Histological examination revealed reduced staining intensity for apoptotic markers in the mucosal and submucosal regions of the duodenum and alveolar structures of the lung in probiotic-treated groups, indicating downregulation of apoptosis and inflammation [76].

Further investigation by the same group demonstrated that probiotics containing Lactobacillus acidophilus and Bifidobacterium, as well as colostrum fermentation products, significantly reduced TNF-α expression in the duodenum and improved liver and lung histology in CCoV-infected mice [36]. Colostrum fermentation probiotics in particular produced normal histological features in the central vein of the liver and in pulmonary sinusoids and alveolar septa, in contrast to the glycogen accumulation, hemorrhage, sinusoidal dilation, lymphocyte infiltration, intra-alveolar hemorrhage, and neutrophil infiltration observed in untreated infected animals [36]. These findings suggest that modulation of the gut microbiome through probiotic supplementation can attenuate the systemic inflammatory response to CCoV infection, potentially reducing disease severity through enhancement of the gut-lung axis of immune regulation.

Host Factors: Age, Co-Infections, and Immunological Naivety

The severity of CCoV infection is intimately linked to host immunological status, with age representing one of the most significant risk factors. Puppies, particularly those under six months of age, exhibit dramatically higher susceptibility to severe disease, a phenomenon confirmed by numerous epidemiological studies across diverse geographic regions [8, 37, 41, 43, 44, 47, 51]. In shelter environments in Sivas, Türkiye, the positivity rate for CCoV was 73.91% in puppies compared to 31.50% in adults [41]. Similarly, a systematic review and meta-analysis of CCoV prevalence in mainland China identified younger dogs as having significantly higher infection rates, with the virus circulating persistently across all seasons but showing seasonal variation in clinical expression [44, 47]. The immunological naivety of young animals, combined with the immaturity of their mucosal immune system, renders them particularly vulnerable to CCoV-induced gastroenteritis.

Co-infections with other enteric and respiratory pathogens profoundly exacerbate CCoV severity. Canine parvovirus (CPV) is the most frequently identified co-pathogen, with co-infection rates ranging from 28.7% to 83.3% in various studies [11, 37, 51]. In farmed raccoon dogs in China, 83.3% of CCoV-positive samples were co-infected with CPV, and the combined infection produced severe diarrhea and fatal outcomes [11]. Similarly, co-infections with canine adenovirus type 2 (CAV-2), canine distemper virus (CDV), canine kobuvirus (CaKV), and norovirus have been documented, with each co-pathogen potentially amplifying the pathogenic effects of CCoV [2, 10, 28, 51]. The development of quadruplex RT-qPCR assays capable of simultaneously detecting CCoV, CRCoV, CAV-2, and canine norovirus represents a significant advancement for diagnosing these complex co-infections in clinical settings [28, 61]. The FAO emphasizes that surveillance of such multi-pathogen interactions in domestic animal populations is critical for food security and zoonotic risk assessment.

Environmental Stressors: Housing, Hygiene, and Management Factors

Environmental factors that compromise immune function or facilitate viral transmission are potent modifiers of CCoV severity. Overcrowding, unsanitary conditions, and poor ventilation in shelters and breeding kennels create conditions conducive to high viral loads and repeated exposure, overwhelming host immune defenses [5, 21, 41]. Studies in Croatian breeding kennels found a CRCoV seroprevalence of 35.03%, with daily cleaning and disinfection showing little effect on infection spread, underscoring the challenge of controlling coronaviruses in high-density environments [58]. In the Southeastern United States, CRCoV was detected in 14% of dogs with canine infectious respiratory disease (CIRD), and the presence of CRCoV, alone or in co-infection, was statistically associated with worse prognosis [49]. Notably, younger dogs and those sampled during warmer weather had significantly higher rates of CRCoV detection, suggesting seasonally variable environmental or behavioral risk factors [49].

Stress-induced immunosuppression, resulting from transportation, boarding, weaning, or concurrent illness, further predisposes dogs to severe CCoV disease. The virus is shed profusely in feces, and environmental contamination of food, water, and bedding facilitates rapid spread within facilities [5]. Vaccination status is a critical modifier of disease severity; unvaccinated or inadequately vaccinated dogs are at substantially higher risk, with one study reporting 96.55% prevalence of CPV and CCoV infections in unvaccinated animals [50]. While current vaccines do not provide sterilizing immunity against all CCoV genotypes, they significantly reduce disease severity and viral shedding [74, 77, 78]. The development of an inactivated vaccine based on the highly virulent CCoV-IIa strain WH2023, formulated with GEL02 adjuvant, produced neutralizing antibody titers reaching 1:5404 after booster vaccination and provided complete protection against homologous challenge, with protective titers persisting for up to 300 days [77]. These findings underscore the importance of maintaining rigorous vaccination protocols, particularly in high-risk environments such as shelters and breeding facilities.

Therapeutic Strategies and Vaccine Development for Canine Coronavirus

The development of effective therapeutic strategies and vaccines against canine coronavirus (CCoV) has become an urgent priority in veterinary medicine, driven by the virus’s remarkable genetic plasticity, its capacity for cross-species transmission, and the emergence of highly virulent pantropic variants. The landscape of antiviral interventions is rapidly evolving, encompassing both host-directed therapies that exploit cellular signaling pathways and direct-acting agents that target viral replication. Concurrently, vaccine development has advanced significantly, with contemporary formulations seeking to address the antigenic diversity engendered by frequent recombination events. This section provides a comprehensive, mechanism-based analysis of current and emerging therapeutic strategies, coupled with a detailed examination of vaccine platforms, their immunogenicity, and the challenges posed by viral evolution.

Immunomodulators and Host-Directed Antiviral Strategies

A paradigm shift in antiviral therapy involves targeting host cellular factors that are usurped by CCoV to facilitate its replication. The aryl hydrocarbon receptor (AhR) has emerged as a critical node in this context. CCoV infection profoundly activates AhR in canine fibrosarcoma (A72) cells [34]. Pharmacological inhibition of AhR using the antagonist CH223191 not only suppresses cell death and enhances viability, but also precipitates a meaningful decline in virus yield and a concomitant reduction in viral nucleocapsid protein (NP) expression [34]. This observation suggests that AhR activation is not merely a bystander effect but is integral to the viral life cycle. The mechanistic link is further substantiated by studies demonstrating that the toxic environmental contaminant 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a potent AhR ligand, substantially amplifies CCoV replication and NP expression in vitro, accompanied by exacerbated cytopathic effects [22]. This interplay between environmental toxicants and viral pathogenesis underscores the potential for AhR to serve as a druggable target.

Several natural products have been identified as effective AhR modulators with antiviral properties. The fungal secondary metabolite 3-O-methylfunicone (OMF), derived from Talaromyces pinophilus, demonstrates marked antiviral activity against CCoV. At non-toxic concentrations, OMF significantly increases cell viability and reduces virus yield, effects that are correlated with a pronounced downregulation of AhR expression [35]. Similarly, 6-pentyl-α-pyrone (6PP), a secondary metabolite from Trichoderma atroviride, exhibits robust antiviral efficacy. Non-toxic concentrations of 6PP enhance cell viability, mitigate morphological signs of cell death, and inhibit viral replication, coinciding with a marked reduction in AhR levels [27]. Expanding this chemical space, funicone-like compounds such as vermistatin (VER) and penisimplicissin (PS) also inhibit CCoV infection at low micromolar concentrations (1 μM and 0.5 μM, respectively), again through a mechanism involving AhR downregulation [31]. Notably, VER and PS also induce lysosomal alkalinization, a process that may independently contribute to their antiviral activity by disrupting viral uncoating or egress [31].

Another promising host target is formyl peptide receptor 2 (FPR2), a G protein-coupled receptor involved in immune modulation. During CCoV infection, the specific FPR2 antagonist WRW4 exacerbates viral replication, leading to increased virus yield and NP expression, alongside worsened cell viability and morphology [26]. Conversely, the FPR2 agonist HP2-20 exerts a protective effect, reducing viral replication [26]. Molecular docking simulations reveal that WRW4 is confined to the core of the canine FPR2 receptor without engaging the extramembrane loops, whereas HP2-20 interacts with both the core and the second extracellular loop (ECL2), forming a more stable complex with increased hydrogen bonds and hydrophobic interactions [26]. This differential receptor engagement explains the opposing functional outcomes and validates FPR2 as an attractive target for antiviral drug development.

The antioxidant and anti-apoptotic enzyme heme oxygenase-1 (HO-1) also demonstrates potent antiviral activity. Induction of HO-1 expression using hemin suppresses CCoV and canine influenza virus (CIV) H3N2 replication in A72 and MDCK cells [25]. Transient overexpression of the canine HO-1 gene, as well as treatment with purified recombinant HO-1 protein, consistently reduces viral RNA and protein expression [25]. The antiviral mechanism is multifaceted, involving both the enzymatic degradation of pro-oxidant heme and the modulation of interferon-related signaling pathways [25]. These findings position HO-1 as a potential therapeutic agent that could be deployed against multiple canine respiratory and enteric viruses.

Interferon-based therapies remain a cornerstone of antiviral defense. Recombinant adenovirus expressing canine interferon lambda 3 (Ad-caIFNλ3) effectively suppresses CCoV replication in both A72 and MDCK cell lines without inducing cytotoxicity [75]. This type III interferon is particularly attractive because its receptor is predominantly expressed on epithelial cells, limiting systemic inflammatory side effects. The adenoviral vector platform also enables efficient delivery, and the antiviral activity extends to canine parvovirus (CPV) and canine distemper virus (CDV), underscoring its broad-spectrum potential [75].

Repurposed Pharmacological Agents and Direct-Acting Antivirals

The urgent need for broad-spectrum antivirals has driven investigation into repurposing approved drugs. Imiquimod, a Toll-like receptor 7 (TLR7) agonist used topically for viral warts, exhibits concentration-dependent antiviral activity against both SARS-CoV-2 and CCoV in epithelial cells [73]. Critically, its anti-coronavirus effect appears to be independent of the canonical TLR7/NF-κB pathway. Instead, imiquimod activates the mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) signaling cascade, a pathway that modulates viral replication [73]. This alternative mechanism, coupled with its immunomodulatory properties, positions imiquimod as a promising broad-spectrum antiviral for respiratory and enteric coronaviruses.

Indomethacin, a nonsteroidal anti-inflammatory drug (NSAID), has demonstrated direct antiviral activity against coronaviruses. In a canine model, oral administration of indomethacin (1 mg/kg body weight) to CCoV-infected dogs resulted in significantly faster clinical recovery compared to treatment with ribavirin (10-15 mg/kg) [79]. The recovery time was comparable to that achieved with a combination therapy of anti-CCoV serum, canine hemoglobin, blood immunoglobulin, and interferon [79]. While the exact mechanism remains to be fully elucidated, indomethacin is known to inhibit viral RNA synthesis in a cyclooxygenase-independent manner, an effect previously observed against SARS-CoV.

Cholesterol-rich lipid rafts are essential for the entry and egress of many enveloped viruses, including CCoV. Depletion of membrane cholesterol using methyl-β-cyclodextrin (MβCD) results in a dose-dependent reduction of CCoV infectivity. Removal of cholesterol from the host cell membrane reduces infection by approximately 68%, while depletion of cholesterol from the viral envelope reduces infectivity by approximately 73% [40]. This demonstrates that the CCoV life cycle is intimately linked to plasma membrane cholesterol homeostasis, and molecules that interfere with lipid metabolism or raft integrity could serve as effective antiviral agents [40].

Vaccine Development: Platforms, Immunogenicity, and Challenges

The development of safe and efficacious vaccines against CCoV is complicated by the virus’s genetic heterogeneity and the emergence of recombinant strains. Traditional inactivated vaccines remain a mainstay of prophylaxis. A novel CCoV-IIa strain, WH2023, isolated from a breeding facility in Wuhan, China, has been developed into an inactivated vaccine formulated with the GEL02 adjuvant [77]. In beagle puppies, this vaccine induced robust neutralizing antibody responses, reaching titers of 1:5404 (12.4 log2) one week after booster vaccination [77]. Vaccinated dogs were fully protected against homologous challenge, whereas unvaccinated controls developed severe gastroenteritis. Remarkably, neutralizing antibody titers remained above 1:32 for up to 300 days, significantly exceeding the duration of protection conferred by commercially available vaccines in China [77]. The WH2023 strain itself is highly virulent, causing 100% morbidity in puppies challenged with a high dose (10⁶ TCID₅₀/mL), which validates its utility as both a vaccine candidate and a challenge strain for efficacy studies [77].

Combination vaccines that incorporate CCoV alongside other core canine pathogens are essential for practical field application. The "Carnican-5R" vaccine, developed in Russia, includes components against canine distemper, parvovirus, coronavirus enteritis, adenovirus infection, and rabies. Double administration at a 21-day interval induced a 5.0-fold increase in CCoV-specific antibody titers, and immunity persisted for at least 12 months [74]. Similarly, the Recombitek® C6/Cv vaccine, which includes a CCoV component alongside distemper, adenovirus, parvovirus, parainfluenza, and Leptospira antigens, has been evaluated for compatibility with rabies vaccination. Co-administration with Rabisin™ did not result in immunological interference, with 100% of puppies seroconverting against all vaccine antigens [78]. The stress of concomitant vaccination is therefore not a barrier to comprehensive protection.

The genetic stability of vaccine seed strains is a critical manufacturing concern. Serial passaging of the CCoV-II vaccine strain 1-71 in A72 cells reveals a predominance of neutral evolution, with only four sites under purifying selection [81]. This suggests that cell-adapted strains maintain genetic fidelity over successive passages, ensuring consistent antigenic composition and immunogenicity. However, the emergence of new variants necessitates continuous surveillance. The CCoV-IIb subtype, which arose from recombination with transmissible gastroenteritis virus (TGEV), is now circulating globally [6, 21]. In China, CCoV-IIa and CCoV-IIb subtypes co-circulate, and recombination events within the spike gene are frequent [4, 10]. The spike gene evolves at a rate of 1.791 × 10⁻³ substitutions/site/year, significantly faster than the M (6.529 × 10⁻⁴) and N (4.775 × 10⁻⁴) genes [4]. This high substitution rate underscores the need for periodic vaccine strain updates.

Novel vaccine strategies are being explored to enhance immunogenicity. The antigenic activity of the CCoV "Rich" strain has been evaluated in rabbits, ferrets, and guinea pigs. A single injection induced virus-neutralizing antibodies (VNA) that peaked at 21 days post-vaccination, with mean titers of 4.08±0.36 log₂ SN₅₀ in rabbits, 3.72–3.77 log₂ SN₅₀ in ferrets, and 4.12±0.34 log₂ SN₅₀ in guinea pigs [80]. Ferrets, which have been underutilized in CCoV vaccine research, demonstrated clearly expressed antigenic activity without adverse local or systemic reactions [80]. This work supports the inclusion of the "Rich" strain in multivalent vaccines.

Probiotic supplementation represents an innovative adjunct to vaccination. Administration of Bifidobacterium and Lactobacillus probiotics to a murine model undergoing CCoV vaccine induction significantly improved hematological parameters, including leukocyte count, hemoglobin, lymphocyte, and neutrophil levels [76]. The probiotic group also exhibited reduced caspase-3 (Casp-3) levels and increased interferon-gamma (IFN-γ) expression, indicating enhanced cellular immunity and reduced apoptosis [76]. Immunohistochemical analysis revealed that probiotic treatment downregulated Casp-3 staining in the duodenal mucosa and alveolar structures of the lung, suggesting a mitigation of vaccine-associated inflammation [76]. A separate study confirmed that colostrum fermentation probiotics (containing Lactobacillus acidophilus and Bifidobacterium) significantly reduced TNF-α expression in the duodenum and improved liver and lung histopathology in CCoV-infected mice [36]. These findings suggest that probiotics can optimize the balance between vaccine-induced immunity and inflammatory pathology.

Diagnostic Tool Development in Support of Vaccination Programs

Accurate and rapid diagnostics are essential for monitoring vaccine efficacy and conducting epidemiological surveillance. The quadruplex RT-qPCR assays for simultaneous detection of CCoV, CRCoV, canine adenovirus type 2, and canine norovirus, or for CCoV alongside rotavirus, parvovirus, and distemper virus, provide high sensitivity (limits of detection of 1.0 × 10² copies/reaction) and excellent repeatability (intra-assay variability 0.19–1.31%) [28, 61]. These multiplex platforms are critical for diagnosing co-infections, which are common in diarrheic dogs and may confound vaccine efficacy trials [8, 10]. The detection of CCoV in 14.2% of dogs in Yulin, China, with CCoV-IIb as the predominant genotype, highlights the need for region-specific vaccine formulations [24]. The emergence of recombinant CCoV strains in wild carnivores, such as red foxes (Vulpes vulpes) and snow leopards (Panthera uncia), further complicates eradication efforts and emphasizes the need for a One Health approach to vaccination [1, 3].

Serological assays are equally important. The development of a double-label time-resolved fluorescence immunoassay (TRFIA) using europium(III) and samarium(III) chelates enables simultaneous detection of CCoV and CPV-2 antigens with sensitivities of 0.51 ng/mL and 0.80 ng/mL, respectively [63]. The clinical sensitivity for CCoV detection reached 95.74%, with a specificity of 93.33% [63]. Similarly, an indirect ELISA employing a multiepitope recombinant S protein (rSP) as the coating antigen demonstrated 82.8% positivity in clinical samples with no cross-reactivity to distemper, parvovirus, or calicivirus [65]. These serological tools are indispensable for assessing herd immunity and the duration of vaccine-induced protection.

The identification of a novel linear B cell epitope (EP-13E8) within the nucleocapsid protein at residues 294-314, which is 100% conserved across diverse CCoV strains but shows low similarity to other coronaviruses, provides a foundation for epitope-based diagnostics and potentially for subunit vaccine design [62]. The monoclonal antibody 13E8 recognizes this epitope, which is surface-exposed on the folded N protein, making it a prime candidate for competitive ELISA development [62].

The evidence synthesized in this section underscores that the control of CCoV requires an integrated strategy: the deployment of host-directed antivirals to manage acute infections, the development of broadly protective vaccines that account for genetic diversity, and the implementation of advanced diagnostic platforms to guide vaccination schedules and monitor for emerging variants. The zoonotic potential of CCoV, exemplified by the isolation of the recombinant CCoV-HuPn-2018 from pneumonia patients in Malaysia and the subsequent detection of related strains in Haiti [9, 12], elevates this pathogen from a concern of purely veterinary relevance to a public health priority. As such, continued investment in therapeutic discovery and vaccine innovation is not merely advisable but essential.

References

[1] Fehér E, Kemenesi G, Görföl T, Wazzani Y, Bodó K, Lanszki J, et al.. Occurrence of Recombinant Canine Coronavirus, Picodicistrovirus, and Circovirus in Red Foxes (Vulpes vulpes) Implies Frequent Virus Transmission Events Among Carnivores. Transboundary and Emerging Diseases. 2025. DOI: https://doi.org/10.1155/tbed/6681119

[2] Mira F, Schiró G, Lanave G, Chiaramonte G, Canuti M, Giudice E, et al.. Molecular Screening and Characterization of Canine Coronavirus Types I and II Strains from Domestic Dogs in Southern Italy, 2019–2021. Transboundary and Emerging Diseases. 2024. DOI: https://doi.org/10.1155/2024/7272785

[3] Olarte‐Castillo XA, Schlecht AB, Calle PP, Whittaker GR. An outbreak of canine coronavirus type 2 in captive snow leopards (Panthera uncia) demonstrates a possible role for felids as mixing vessels for alphacoronaviruses. bioRxiv. 2024. DOI: https://doi.org/10.1101/2024.03.25.586607

[4] Shi K, Shi Y, Shi Y, Pan Y, Feng S, Feng Z, et al.. Genetic and Evolutionary Analysis of Canine Coronavirus in Guangxi Province, China, for 2021–2024. Veterinary Sciences. 2024. DOI: https://doi.org/10.3390/vetsci11100456

[5] Tesfaye M, Mihret T, Enbiyale G, Workineh D. Review on Canine Coronavirus Disease; Its Clinical Management and Zoonotic Spillover. Austin Journal of Public Health and Epidemiology. 2024. DOI: https://doi.org/10.26420/austinjpublichealthepidemiol.2024.1156

[6] Buonavoglia A, Pellegrini F, Decaro N, Galgano M, Pratelli A. A One Health Perspective on Canine Coronavirus: A Wolf in Sheep’s Clothing?. Microorganisms. 2023. DOI: https://doi.org/10.3390/microorganisms11040921

[7] Liu Y, Deng Y, Niu S, Zhu N, Song J, Zhang X, et al.. Discovery and identification of a novel canine coronavirus causing a diarrhea outbreak in Vulpes.. Science Bulletin. 2023. DOI: https://doi.org/10.1016/j.scib.2023.09.011

[8] Li N, Bai Y, Liu R, Guo Z, Yan X, Xiang K, et al.. Prevalence and genetic diversity of canine coronavirus in northeastern China during 2019-2021.. Comparative Immunology, Microbiology & Infectious Diseases. 2023. DOI: https://doi.org/10.2139/ssrn.4169967

[9] Vlasova A, Diaz A, Damtie D, Xiu L, Toh T, Lee JSY, et al.. Novel Canine Coronavirus Isolated from a Hospitalized Pneumonia Patient, East Malaysia. Clinical Infectious Diseases. 2021. DOI: https://doi.org/10.1093/cid/ciab456

[10] He H, Zhang W, Liang J, Lu M, Wang R, Li G, et al.. Etiology and genetic evolution of canine coronavirus circulating in five provinces of China, during 2018–2019. Microbial Pathogenesis. 2020. DOI: https://doi.org/10.1016/j.micpath.2020.104209

[11] Lu R, Cao H, Yang W, Fu J, Qian T, Zhang C, et al.. Emergence of Canine Parvovirus Type 2a and Canine Enteric Coronavirus in Diarrheal Outbreaks Among Farmed Raccoon Dogs in China. Transboundary and Emerging Diseases. 2025. DOI: https://doi.org/10.1155/tbed/8880613

[12] Lednicky J, Tagliamonte M, White SK, Blohm GM, Alam MM, Iovine NM, et al.. Isolation of a Novel Recombinant Canine Coronavirus From a Visitor to Haiti: Further Evidence of Transmission of Coronaviruses of Zoonotic Origin to Humans. Clinical Infectious Diseases. 2021. DOI: https://doi.org/10.1093/cid/ciab924

[13] Zehr JD, Pond SKK, Martin D, Ceres KM, Whittaker G, Goodman L, et al.. Recent Zoonotic Spillover and Tropism Shift of a Canine Coronavirus Is Associated with Relaxed Selection and Putative Loss of Function in NTD Subdomain of Spike Protein. bioRxiv. 2021. DOI: https://doi.org/10.3390/v14050853

[14] Gray GC, Vlasova A, Lednicky JA, Nguyen-Tien T, Shittu I, Li F. Emerging Respiratory Virus Threats from Influenza D and Canine Coronavirus HuPn-2018. Emerging Infectious Diseases. 2026. DOI: https://doi.org/10.3201/eid3201.251764

[15] . The knotty biology of canine coronavirus: A worrying model of coronaviruses' danger. Research in Veterinary Science. 2021. DOI: https://doi.org/10.1016/j.rvsc.2021.11.014

[16] Tian Z, Pan Q, Zheng M, Deng Y, Guo P, Cong F, et al.. Molecular characterization of the FCoV-like canine coronavirus HLJ-071 in China. BMC Veterinary Research. 2021. DOI: https://doi.org/10.1186/s12917-021-03073-8

[17] Gan J, Tang Y, Lv H, Xiong W, Tian X. Identification and phylogenetic analysis of two canine coronavirus strains. Animal Diseases. 2021. DOI: https://doi.org/10.1186/s44149-021-00013-9

[18] Rowland H, Holding E, Falces PM, Wissink-Argilaga N, Stidworthy M, Denk D, et al.. Canine coronavirus subtype 2a associated with outbreaks of fatal diarrhoea in bush dog (Speothos venaticus) groups.. Schweizer Archiv für Tierheilkunde. 2021. DOI: https://doi.org/10.17236/sat00320

[19] Alfano F, Dowgier G, Valentino MP, Galiero G, Tinelli A, Nicola D, et al.. Identification of Pantropic Canine Coronavirus in a Wolf (Canis lupus italicus) in Italy. Journal of Wildlife Diseases. 2019. DOI: https://doi.org/10.7589/2018-07-182

[20] Han Z, Wang H, Liu X, Tian Z, Gong Q, Zhang X, et al.. Cross-species transmission alert: a novel canine-raccoon dog coronavirus infecting an Amur Tiger in China. Frontiers in Microbiology. 2026. DOI: https://doi.org/10.3389/fmicb.2026.1764349

[21] Ntafis V, Papanastassopoulou M, Xylouri E. Canine coronavirus: not an ‘innocuous’ virus. Journal of the Hellenic Veterinary Medical Society. 2017. DOI: https://doi.org/10.12681/JHVMS.15480

[22] Sorbo LD, Cerracchio C, Serra F, Canzanella S, Giugliano R, Lambiase S, et al.. Canine coronavirus infection is intensified by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Archives of Toxicology. 2025. DOI: https://doi.org/10.1007/s00204-025-03981-w

[23] Wijerathne SVT, Pandit R, Ezeuko CC, Matthews QL. Comparative Examination of Feline Coronavirus and Canine Coronavirus Effects on Extracellular Vesicles Acquired from A-72 Canine Fibrosarcoma Cell Line. Veterinary Sciences. 2025. DOI: https://doi.org/10.3390/vetsci12050477

[24] Lian C, Yao X, Lv Z, Zhang X, Shao J. Genetic diversity of canine coronavirus identified in dogs in yulin city, southern China.. Virology. 2025. DOI: https://doi.org/10.1016/j.virol.2025.110528

[25] Kim J, Kim D, Lim K, Lee J, Park S, Song C, et al.. Antiviral effects of heme oxygenase-1 against canine coronavirus and canine influenza virus in vitro.. Journal of Microbiology. 2025. DOI: https://doi.org/10.71150/jm.2501029

[26] Giugliano R, Iovane V, Gentile A, Sorbo LD, Cuomo P, Salvatore M, et al.. Involvement of formyl peptide receptor 2 in canine coronavirus infection: in vitro and in Silico approaches. Virology Journal. 2025. DOI: https://doi.org/10.1186/s12985-025-02984-4

[27] Cerracchio C, Sorbo LD, Serra F, Staropoli A, Amoroso M, Vinale F, et al.. Fungal metabolite 6-pentyl-α-pyrone reduces canine coronavirus infection. Heliyon. 2024. DOI: https://doi.org/10.1016/j.heliyon.2024.e28351

[28] Shi Y, Long F, Shi K, He M, Shi Y, Feng S, et al.. A Quadruplex Reverse Transcription Quantitative Polymerase Chain Reaction for Detecting Canine Coronavirus, Canine Rotavirus, Canine Parvovirus, and Canine Distemper Virus. Microbiology Research. 2024. DOI: https://doi.org/10.3390/microbiolres15020049

[29] Wu S, He X, Zhang B, An L, You L, Luo S, et al.. Molecular epidemiology and genetic diversity of canine coronavirus from domestic dogs in Chengdu, China from 2020 to 2021 using a multiplex RT-PCR.. Infection, Genetics and Evolution. 2023. DOI: https://doi.org/10.1016/j.meegid.2023.105463

[30] Pandit R, Ipinmoroti AO, Crenshaw BJ, Li T, Matthews QL. Canine Coronavirus Infection Modulates the Biogenesis and Composition of Cell-Derived Extracellular Vesicles. Biomedicines. 2023. DOI: https://doi.org/10.3390/biomedicines11030976

[31] Cerracchio C, Salvatore M, Sorbo LD, Serra F, Amoroso M, DellaGreca M, et al.. In Vitro Evaluation of Antiviral Activities of Funicone-like Compounds Vermistatin and Penisimplicissin against Canine Coronavirus Infection. Antibiotics. 2023. DOI: https://doi.org/10.3390/antibiotics12081319

[32] Attipa C, Warr A, Epaminondas D, O’Shea M, Hanton AJ, Fletcher S, et al.. Emergence and spread of feline infectious peritonitis due to a highly pathogenic canine/feline recombinant coronavirus. bioRxiv. 2024. DOI: https://doi.org/10.1101/2023.11.08.566182

[33] Vieira FV, Nalesso RF, Panegossi LC, Godoy IAP, Baptistella JC, Cardoso T. Pantropic canine coronavirus induces canine M1 macrophage polarization in vitro. PubVet. 2023. DOI: https://doi.org/10.31533/pubvet.v17n6e1405

[34] Cerracchio C, Serra F, Amoroso M, Fiorito F. Canine Coronavirus Activates Aryl Hydrocarbon Receptor during In Vitro Infection. Viruses. 2022. DOI: https://doi.org/10.3390/v14112437

[35] Cerracchio C, Iovane V, Salvatore M, Amoroso M, Dakroub H, DellaGreca M, et al.. Effectiveness of the Fungal Metabolite 3-O-Methylfunicone towards Canine Coronavirus in a Canine Fibrosarcoma Cell Line (A72). Antibiotics. 2022. DOI: https://doi.org/10.3390/antibiotics11111594

[36] Hamid IS, Ekowati J, Solfaine R, Chhetri S, Purnama M. Efficacy of Probiotic on Duodenal TNF-α Expression and the Histological Findings in the Liver and Lung in Animal Model Canine Coronavirus. Pharmacognosy Journal. 2022. DOI: https://doi.org/10.5530/pj.2022.14.76

[37] Tekelioğlu BK. Seroepidemiological and Clinicopathological Investigation of Canine Coronavirus Infection in Dogs, in Türkiye. Turkish Journal of Agriculture - Food Science and Technology. 2022. DOI: https://doi.org/10.24925/turjaf.v10i10.1884-1892.5375

[38] Alfano F, Fusco G, Mari V, Occhiogrosso L, Miletti G, Brunetti R, et al.. Circulation of pantropic canine coronavirus in autochthonous and imported dogs, Italy. Transboundary and Emerging Diseases. 2020. DOI: https://doi.org/10.1111/tbed.13542

[39] Chen S, Liu D, Tian J, Kang H, Guo D, Jiang Q, et al.. Molecular characterization of HLJ-073, a recombinant canine coronavirus strain from China with an ORF3abc deletion. Archives of Virology. 2019. DOI: https://doi.org/10.1007/s00705-019-04296-9

[40] Pratelli A, Colao V. Role of the lipid rafts in the life cycle of canine coronavirus. Journal of General Virology. 2015. DOI: https://doi.org/10.1099/vir.0.070870-0

[41] Turan T, Işıdan H, Atasoy M. Molecular Detection and Partial Membrane Gene Sequence-Based Characterization of Canine Coronavirus in Diarrheal Shelter Dogs in Sivas, Türkiye. Veterinary Sciences and Practices. 2025. DOI: https://doi.org/10.17094/vetsci.1708883

[42] Al.Bayati HAM, Al.khateeb ZD. Molecular Characterization of Canine Coronavirus Strains Circulating in Baghdad and Wasit Provinces, Iraq. Natural and Engineering Sciences. 2025. DOI: https://doi.org/10.28978/nesciences.1811142

[43] Santos HO, Santos EMS, Oliveira HdSd, Santos WSd, Tupy AA, Souza EG, et al.. Screening for canine coronavirus, canine influenza virus, and severe acute respiratory syndrome coronavirus 2 in dogs during the coronavirus disease-2019 pandemic. Veterinary World. 2023. DOI: https://doi.org/10.14202/vetworld.2023.1772-1780

[44] Dong B, Zhang X, Bai J, Zhang G, Li C, Lin W. Epidemiological investigation of canine coronavirus infection in Chinese domestic dogs: A systematic review and data synthesis.. Preventive Veterinary Medicine. 2022. DOI: https://doi.org/10.1016/j.prevetmed.2022.105792

[45] Sha X, Li Y, Huang J, Zhou Q, Song X, Zhang B. Detection and molecular characteristics of canine coronavirus in Chengdu city, Southwest China from 2020 to 2021.. Microbial Pathogenesis. 2022. DOI: https://doi.org/10.1016/j.micpath.2022.105548

[46] Cunningham-Oakes E, Pilgrim J, Darby AC, Appleton C, Jewell C, Rowlingson B, et al.. Emerging Variants of Canine Enteric Coronavirus Associated with Outbreaks of Gastroenteric Disease. Emerging Infectious Diseases. 2024. DOI: https://doi.org/10.3201/eid3006.231184

[47] Chen C, Ji X, Zhang T, Ge L, Sun M, Yang M, et al.. A systematic review and meta-analysis of canine enteric coronavirus prevalence in dogs of mainland China. Virology Journal. 2024. DOI: https://doi.org/10.1186/s12985-024-02425-8

[48] Abdelgadir A, Vlasova A, Gray G. Susceptibility of different cell lines to the novel canine coronavirus CCoV‐HuPn‐2018. Influenza and Other Respiratory Viruses. 2021. DOI: https://doi.org/10.1111/irv.12882

[49] Luca ED, Álvarez-Narváez S, Baptista R, Maboni G, Blas-Machado U, Sanchez S. Epidemiologic investigation and genetic characterization of canine respiratory coronavirus in the Southeastern United States. Journal of Veterinary Diagnostic Investigation. 2023. DOI: https://doi.org/10.1177/10406387231213662

[50] Agnihotri D. Molecular Detection Based Epidemiology of Canine Parvovirus and Canine Coronavirus Infection in Diarrheic Dogs in Haryana. Journal of Animal Research. 2018. DOI: https://doi.org/10.30954/2277-940X.06.2018.5

[51] Wang X, Li C, Guo D, Wei S, Geng Y, Wang E, et al.. Co-Circulation of Canine Coronavirus I and IIa/b with High Prevalence and Genetic Diversity in Heilongjiang Province, Northeast China. PLoS ONE. 2016. DOI: https://doi.org/10.1371/journal.pone.0146975

[52] Ferrara G, Lerro R, Shin H, Pagnini U. Serological and molecular evidence of canine enteric coronavirus in southern Italy. Scientific Reports. 2026. DOI: https://doi.org/10.1038/s41598-026-35787-w

[53] Cunningham-Oakes E, Pilgrim J, Darby A, Appleton C, Jewell C, Rowlingson B, et al.. Emerging variants of canine enteric coronavirus associated with seasonal outbreaks of severe canine gastroenteric disease. bioRxiv. 2022. DOI: https://doi.org/10.1101/2022.10.03.510536

[54] Karapınar Z, Timurkan MÖ. MOLECULAR CHARACTERIZATION OF CANINE CORONAVIRUS: PHYLOGENETIC ANALYSIS OF PARTIAL MEMBRANE GENE. The Veterinary Journal. 2023. DOI: https://doi.org/10.36483/vanvetj.1302205

[55] Ren Y, Huang J, Chen X, Tang C, Yue H. Characteristics of an emerging canine respiratory coronavirus in China. Veterinary Quarterly. 2025. DOI: https://doi.org/10.1080/01652176.2025.2574506

[56] Zhou H, Li H, Sun X, Lin J, Zhang C, Zhao J, et al.. Rapid diagnosis of Canine respiratory coronavirus, Canine influenza virus, Canine distemper virus and Canine parainfluenza virus with a Taqman probe-based multiplex real-time PCR.. Journal of Virological Methods. 2024. DOI: https://doi.org/10.1016/j.jviromet.2024.114960

[57] Goralskii L, Radzіkhovsky N, Dyshkant О, Dunaievska O, Sokulskiy I. Experimental study of tropism in cultivated canine coronavirus in the small intestine of puppies. Regulatory Mechanisms in Biosystems. 2019. DOI: https://doi.org/10.15421/021972

[58] Stevanović V, Maljković MM, Gracin K, Benvin I, Starešina V, Kovač S, et al.. Seroprevalence of canine respiratory coronavirus in breeding kennels in Croatia. Veterinarski arhiv (Tisak). 2023. DOI: https://doi.org/10.24099/vet.arhiv.1602

[59] Fisher CJ, Khrongsee P, Subramaniam K, Pushinsky AD, Stevenson V, Crawford C, et al.. Acute Respiratory Distress Syndrome in a Dog With Canine Respiratory Coronavirus Infection. Journal of Veterinary Emergency and Critical Care. 2026. DOI: https://doi.org/10.1111/vec.70113

[60] Pratelli A, Cirone F. The Polarity of Entry and Release of Canine Coronavirus FromEpithelial Cells. Biomedical Journal of Scientific and Technical Research. 2018. DOI: https://doi.org/10.26717/bjstr.2018.02.000675

[61] Shi K, Shi Y, Shi Y, Long F, Yin Y, Pan Y, et al.. Establishment of a Quadruplex RT-qPCR for the Detection of Canine Coronavirus, Canine Respiratory Coronavirus, Canine Adenovirus Type 2, and Canine Norovirus. Pathogens. 2024. DOI: https://doi.org/10.3390/pathogens13121054

[62] Tian X, Tang Y, Gan J, Ye J. A novel linear B cell epitope of the canine coronavirus nucleocapsid protein identified by a monoclonal antibody.. Veterinary Microbiology. 2024. DOI: https://doi.org/10.1016/j.vetmic.2024.110098

[63] Li L, Chen C, Liang H, Dong W, Leontiev VN, Voytov IV. Development of a time-resolved fluorescence immunoassay kit for detecting canine coronavirus and parvovirus through double labeling. Virology Journal. 2024. DOI: https://doi.org/10.1186/s12985-024-02302-4

[64] Radzyhovskyi M, Dyshkant O, Sokulskyi I, Kuriata N, Pishchanskyi O, Rudoi O, et al.. COMPARATIVE SENSITIVITY OF CELL CULTURES TO CANINE CORONAVIRUS CLINICAL ISOLATES. Scientific and Technical Bulletin оf State Scientific Research Control Institute of Veterinary Medical Products and Fodder Additives аnd Institute of Animal Biology. 2024. DOI: https://doi.org/10.36359/scivp.2024-25-2.14

[65] Hao Y, Li S, Zhang G, Xu Y, Long G, Lu X, et al.. Establishment of an indirect ELISA-based method involving the use of a multiepitope recombinant S protein to detect antibodies against canine coronavirus. Archives of Virology. 2021. DOI: https://doi.org/10.1007/s00705-021-05072-4

[66] Awad R, Hassan S, Khalil W. Epidemiology and molecular diagnosis of canine coronavirus in Egypt: evaluation of different tests used for its diagnosis. Bulgarian Journal of Veterinary Medicine. 2020. DOI: https://doi.org/10.15547/bjvm.2019-0024

[67] Hyeon L, Yang D, Park Y, Lee H, Kim H, Hyun B. Evaluation of hemagglutination inhibition test for canine respiratory coronavirus antibodies and seroprevalence in Korean dogs. Korean Journal of Veterinary Research. 2023. DOI: https://doi.org/10.14405/kjvr.20230037

[68] Yoon S, Seo K, Song K. Clinical evaluation of a rapid diagnostic test kit for detection of canine coronavirus. . 2018. DOI: https://doi.org/10.14405/KJVR.2018.58.1.27

[69] Wang J, Luo Y, Liang L, Li J, Cui S. A fast and simple one-step duplex PCR assay for canine distemper virus (CDV) and canine coronavirus (CCoV) detection. Archives of Virology. 2018. DOI: https://doi.org/10.1007/s00705-018-3982-8

[70] Nguyen DV, Terada Y, Minami S, Yonemitsu K, Nagata N, Le T, et al.. Characterization of canine coronavirus spread among domestic dogs in Vietnam. Journal of Veterinary Medical Science. 2016. DOI: https://doi.org/10.1292/jvms.16-0538

[71] Khan MAA, Schoene K, Cashman J, Wahed AAE, Truyen U. Evaluation of a simple ultrafiltration method for concentration of infective canine parvovirus and feline coronavirus from cell culture supernatants. Journal of Virological Methods. 2022. DOI: https://doi.org/10.1016/j.jviromet.2022.114628

[72] Lu S, Chen Y, Qin K, Zhou J, Lou Y, Tan W. Genetic and antigenic characterization of recombinant nucleocapsid proteins derived from canine coronavirus and canine respiratory coronavirus in China. Science China Life Sciences. 2016. DOI: https://doi.org/10.1007/s11427-016-5038-1

[73] Vicente J, Figueredo FAP, Mantovani S, Papademetrio D, Nemirovsky S, Barquero A, et al.. Imiquimod, a Promising Broad-Spectrum Antiviral, Prevents SARS-CoV-2 and Canine Coronavirus Multiplication Through the MAPK/ERK Signaling Pathway. Viruses. 2025. DOI: https://doi.org/10.3390/v17060801

[74] Klimova AA, Komarova AA, Kiselev AM, Galkina TS. Testing of vaccine against canine distemper, parvovirus and coronavirus enteritis, adenovirus infection and dog rabies for its antigenic properties. Veterinary Science Today. 2025. DOI: https://doi.org/10.29326/2304-196x-2025-14-2-179-185

[75] Kim D, Han S, Go H, Kim D, Kim J, Lee J, et al.. Antiviral activity of canine interferon lambda 3 expressed using a recombinant adenovirus against canine coronavirus, canine parvovirus, and canine distemper virus. Veterinary research communications. 2022. DOI: https://doi.org/10.1007/s11259-022-10000-1

[76] Hamid I, Fikri F, Kuncorojakti S, Purnama M, Maslamama S, Rehman S, et al.. Beneficial immunomodulatory and hematological effects of bifidobacterium and lactobacillus probiotics in canine coronavirus vaccine induction in a murine model. Open Veterinary Journal. 2026. DOI: https://doi.org/10.5455/ovj.2026.v16.i1.30

[77] Zhang X, Li Y, Liu X, Zhou M, Zhao L. Identification and vaccine efficacy evaluation of a canine coronavirus isolated in central China.. Veterinary Microbiology. 2026. DOI: https://doi.org/10.1016/j.vetmic.2026.110879

[78] Thibault J, Bouvet J, Cupillard L, Cariou C, Oberli F. Compatibility between a rabies vaccine and two canine combined vaccines against canine distemper, adenovirosis, parvovirosis, parainfluenza virus disease and leptospirosis, with or without canine coronavirus. Comparative Immunology, Microbiology & Infectious Diseases. 2022. DOI: https://doi.org/10.1016/j.cimid.2022.101803

[79] Xu T, Gao X, Wu Z, Selinger D, Zhou Z. Indomethacin has a potent antiviral activity against SARS CoV-2 in vitro and canine coronavirus in vivo. bioRxiv. 2020. DOI: https://doi.org/10.1101/2020.04.01.017624

[80] Komarova AA, Galkina TS. Antigenic Activity of Canine Enteric Coronavirus Strain "Rich" in Experiments with Rabbits, Ferrets and Guinea Pigs. Russian Journal of Veterinary Pathology. 2024. DOI: https://doi.org/10.23947/2949-4826-2023-22-4-12-18

[81] Barros I, Silva SOdS, Taniwaki S. Molecular stability of a vaccine strain of Canine coronavirus after serial passages in A 72 cells. . 2017. DOI: https://doi.org/10.11606/issn.1678-4456.bjvras.2017.111310